Clinical trial results:
A Phase 2B, Randomised, Double Blind, Vehicle-controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Subjects With Mild to Moderate Chronic Plaque Psoriasis

Summary

EudraCT number	2018-003051-38
Trial protocol	LV DE HU BG PL DK
Global end of trial date	20 April 2021

Results information

Result version number	v2 (current)
This version publication date	14 July 2022
First version publication date	22 April 2022
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	B7931023

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03850483
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 August 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 April 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the efficacy of multiple dose levels of PF-06700841 versus vehicle on change from baseline in psoriasis area and severity index (PASI) score in subjects with mild to moderate plaque psoriasis.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 April 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 26
Country: Number of subjects enrolled	Bulgaria: 31
Country: Number of subjects enrolled	Canada: 25
Country: Number of subjects enrolled	Germany: 45
Country: Number of subjects enrolled	Hungary: 5
Country: Number of subjects enrolled	Japan: 27
Country: Number of subjects enrolled	Latvia: 19
Country: Number of subjects enrolled	Poland: 12
Country: Number of subjects enrolled	United States: 153
Worldwide total number of subjects	343
EEA total number of subjects	112

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	293
From 65 to 84 years	50
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Overall 344 subjects were enrolled and 343 were treated.

Period 1

Period 1 title	Overall Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Vehicle Once Daily (QD)

Arm description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 QD for a maximum of 12 weeks.

Arm title	PF-06700841 0.1% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.1 percent (%) cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.1% cream QD for a maximum of 12 weeks.

Arm title	PF-06700841 0.3% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.3% cream QD for a maximum of 12 weeks.

Arm title	PF-06700841 1.0% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 1.0% cream QD for a maximum of 12 weeks.

Arm title	PF-06700841 3.0% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 3.0% cream QD for a maximum of 12 weeks.

Arm title	Pooled Vehicle Twice Daily (BID)

Arm description:

During stage 1 and 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 BID for a maximum of 12 weeks.

Arm title	PF-06700841 0.3% BID

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.3% cream BID for a maximum of 12 weeks.

Arm title	PF-06700841 1.0% BID

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 1.0% cream BID for a maximum of 12 weeks.

Arm title	PF-06700841 3.0% BID

Arm description:

During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 3.0% cream BID for a maximum of 12 weeks.

Number of subjects in period 1	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD
Started	37	37	37
Completed	37	37	37

Number of subjects in period 1	PF-06700841 1.0% QD	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)
Started	36	37	49
Completed	36	37	49

Number of subjects in period 1	PF-06700841 0.3% BID	PF-06700841 1.0% BID	PF-06700841 3.0% BID
Started	36	36	38
Completed	36	36	38

Period 2

Period 2 title	Treatment for Stage 1
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	No
Arm title	Stage 1: Vehicle Once Daily (QD)

Arm description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 0.1% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.1% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 0.3% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.3% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 1.0% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD

for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 1.0% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 3.0% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 3.0% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: Vehicle BID

Arm description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 BID for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 0.3% BID

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.3% cream BID for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 1.0% BID

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental

Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 1.0% cream BID for a maximum of 12 weeks.

Number of subjects in period 2	Stage 1: Vehicle Once Daily (QD)	Stage 1: PF-06700841 0.1% QD	Stage 1: PF-06700841 0.3% QD
Started	37	37	37
Treated	37	37	37
Completed	29	29	26
Not completed	8	8	11
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	4	4	2
Physician decision	-	-	-
Adverse event, non-fatal	1	1	3
Non-Compliance With Study Drug	-	-	1
No Longer Met Eligibility Criteria	-	-	-
Randomized but not Treated	-	-	-
Unspecified	-	-	-
Refused Further Treatment	1	-	2
Lost to follow-up	-	1	1
Protocol deviation	1	-	-
Lack of efficacy	1	2	2

Number of subjects in period 2	Stage 1: PF-06700841 1.0% QD	Stage 1: PF-06700841 3.0% QD	Stage 1: Vehicle BID
Started	36	37	38
Treated	36	37	37
Completed	30	28	27
Not completed	6	9	11
Adverse event, serious fatal	-	-	1
Consent withdrawn by subject	2	2	1
Physician decision	-	-	1
Adverse event, non-fatal	-	2	-
Non-Compliance With Study Drug	-	-	-
No Longer Met Eligibility Criteria	-	-	1
Randomized but not Treated	-	-	1
Unspecified	-	2	1
Refused Further Treatment	-	1	-

Lost to follow-up	1	-	1
Protocol deviation	-	-	-
Lack of efficacy	3	2	4

Number of subjects in period 2	Stage 1: PF-06700841 0.3% BID	Stage 1: PF-06700841 1.0% BID
Started	36	36
Treated	36	36
Completed	25	30
Not completed	11	6
Adverse event, serious fatal	-	-
Consent withdrawn by subject	2	3
Physician decision	-	-
Adverse event, non-fatal	2	2
Non-Compliance With Study Drug	-	-
No Longer Met Eligibility Criteria	-	-
Randomized but not Treated	-	-
Unspecified	-	-
Refused Further Treatment	1	-
Lost to follow-up	2	-
Protocol deviation	1	-
Lack of efficacy	3	1

Period 3

Period 3 title	Follow-up for Stage 1
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	No
Arm title	Stage 1: Vehicle Once Daily (QD)

Arm description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 0.1% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.1 % cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.1% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 0.3% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.3% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 1.0% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 1.0% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 3.0% QD

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 3.0% cream QD for a maximum of 12 weeks.

Arm title	Stage 1: Vehicle Twice Daily (BID)

Arm description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 BID for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 0.3% BID

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 0.3% cream BID for a maximum of 12 weeks.

Arm title	Stage 1: PF-06700841 1.0% BID

Arm description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 1.0% cream BID for a maximum of 12 weeks.

Number of subjects in period 3	Stage 1: Vehicle Once Daily (QD)	Stage 1: PF-06700841 0.1% QD	Stage 1: PF-06700841 0.3% QD
Started	37	37	37
Completed	37	34	35
Not completed	0	3	2
Physician decision	-	-	-
Consent withdrawn by subject	-	-	-
Refused Further Study Procedures	-	1	-
Adverse event, non-fatal	-	-	1
Unspecified	-	2	-
Lack of efficacy	-	-	1

Number of subjects in period 3	Stage 1: PF-06700841 1.0% QD	Stage 1: PF-06700841 3.0% QD	Stage 1: Vehicle Twice Daily (BID)
Started	36	37	37
Completed	34	34	33
Not completed	2	3	4
Physician decision	-	1	-
Consent withdrawn by subject	-	-	-
Refused Further Study Procedures	-	2	2
Adverse event, non-fatal	-	-	1
Unspecified	2	-	1
Lack of efficacy	-	-	-

Number of subjects in period 3	Stage 1: PF-06700841 0.3% BID	Stage 1: PF-06700841 1.0% BID
Started	36	36
Completed	34	33
Not completed	2	3
Physician decision	1	-
Consent withdrawn by subject	1	2
Refused Further Study Procedures	-	-
Adverse event, non-fatal	-	-
Unspecified	-	-
Lack of efficacy	-	1

Period 4

Period 4 title	Treatment for Stage 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms	
Are arms mutually exclusive?	No
Arm title	Stage 2: Vehicle BID

Arm description:

During stage 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 BID for a maximum of 12 weeks.

Arm title	Stage 2: PF-06700841 3.0% BID

Arm description:

During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 3.0% cream BID for a maximum of 12 weeks.

Number of subjects in period 4	Stage 2: Vehicle BID	Stage 2: PF-06700841 3.0% BID
Started	12	38
Completed	7	27
Not completed	5	11
Consent withdrawn by subject	2	5
Physician decision	-	1
Adverse event, non-fatal	-	1
Refused Further Treatment	1	-
Lost to follow-up	-	3
No Longer Meets Eligibility Criteria	-	1
Lack of efficacy	1	-
Protocol deviation	1	-

Period 5	
Period 5 title	Follow-up For Stage 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms	
Are arms mutually exclusive?	No
Arm title	Stage 2: Vehicle BID

Arm description:

During stage 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied placebo cream matched to PF-06700841 BID for a maximum of 12 weeks.

Arm title	Stage 2: PF-06700841 3.0% BID

Arm description:

During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	Brepocitinib
Investigational medicinal product code	PF-06700841
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subjects applied brepocitinib 3.0% cream BID for a maximum of 12 weeks.

Number of subjects in period 5	Stage 2: Vehicle BID	Stage 2: PF-06700841 3.0% BID
Started	12	38
Completed	12	36
Not completed	0	2
Unspecified	-	1
Lost to follow-up	-	1

Baseline characteristics

Reporting groups	
Reporting group title	Vehicle Once Daily (QD)
Reporting group description:	
During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.1% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.1 percent (%) cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.3% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 1.0% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 3.0% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Pooled Vehicle Twice Daily (BID)
Reporting group description:	
During stage 1 and 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.3% BID
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 1.0% BID
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 3.0% BID
Reporting group description:	
During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	

Reporting group values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD
Number of subjects	37	37	37
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	31	31	33
From 65-84 years	6	6	4
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	48.6	51.8	51.4
standard deviation	± 15.83	± 12.49	± 12.26
Sex: Female, Male			
Units: Subjects			
Female	12	10	7
Male	25	27	30
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	6	4	6
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	0	2
White	30	33	28
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	5	2	4
Not Hispanic or Latino	32	35	33
Unknown or Not Reported	0	0	0

Reporting group values	PF-06700841 1.0% QD	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)
Number of subjects	36	37	49
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	31	35	41
From 65-84 years	5	2	8
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	49.4	48.4	50.9
standard deviation	± 15.30	± 12.37	± 12.85
Sex: Female, Male			
Units: Subjects			
Female	6	13	18
Male	30	24	31

Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	1	0
Asian	6	4	3
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	30	32	45
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	2	8
Not Hispanic or Latino	35	35	39
Unknown or Not Reported	0	0	2

Reporting group values	PF-06700841 0.3% BID	PF-06700841 1.0% BID	PF-06700841 3.0% BID
Number of subjects	36	36	38
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	31	25	35
From 65-84 years	5	11	3
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	48.2	50.9	48.9
standard deviation	± 13.58	± 16.45	± 12.93
Sex: Female, Male Units: Subjects			
Female	11	11	14
Male	25	25	24
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	6	3	2
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	1	2
White	30	31	34
More than one race	0	1	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	3	3	7

Not Hispanic or Latino	33	33	31
Unknown or Not Reported	0	0	0

Reporting group values	Total		
Number of subjects	343		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	293		
From 65-84 years	50		
85 years and over	0		
Age Continuous Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male Units: Subjects			
Female	102		
Male	241		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	2		
Asian	40		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	7		
White	293		
More than one race	1		
Unknown or Not Reported	0		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	35		
Not Hispanic or Latino	306		
Unknown or Not Reported	2		

End points

End points reporting groups

Reporting group title	Vehicle Once Daily (QD)
Reporting group description:	
During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.1% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.1 percent (%) cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.3% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 1.0% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 3.0% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Pooled Vehicle Twice Daily (BID)
Reporting group description:	
During stage 1 and 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.3% BID
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 1.0% BID
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 3.0% BID
Reporting group description:	
During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Stage 1: Vehicle Once Daily (QD)
Reporting group description:	
During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Stage 1: PF-06700841 0.1% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Stage 1: PF-06700841 0.3% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Stage 1: PF-06700841 1.0% QD
Reporting group description:	
During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.	

Reporting group title	Stage 1: PF-06700841 3.0% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: Vehicle BID

Reporting group description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 0.3% BID

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 1.0% BID

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: Vehicle Once Daily (QD)

Reporting group description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 0.1% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.1 % cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 0.3% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 1.0% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 3.0% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: Vehicle Twice Daily (BID)

Reporting group description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 0.3% BID

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 1: PF-06700841 1.0% BID

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 2: Vehicle BID

Reporting group description:

During stage 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 2: PF-06700841 3.0% BID

Reporting group description:

During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 2: Vehicle BID

Reporting group description:

During stage 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Stage 2: PF-06700841 3.0% BID

Reporting group description:

During stage 2 of the study subjects topically applied PF-06700841 3.0% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	Vehicle Once Daily (QD)
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 0.1% QD
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied PF-06700841 0.1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 0.3% QD
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 1.0% QD
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied PF-06700841 1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 3.0% QD
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied PF-06700841 3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	Pooled Vehicle BID
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 and 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 0.3% BID
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 1.0% BID
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 1 of the study subjects topically applied PF-06700841 1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Subject analysis set title	PF-06700841 3.0% BID
Subject analysis set type	Safety analysis

Subject analysis set description:

During stage 2 of the study subjects topically applied PF-06700841 3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

End point title	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

End point description:

PASI score (0-72, higher score = greater severity) measured severity and extent of psoriasis. The 4 regions of the body parts are head (10%),arms (20%),trunk (30%) and legs (40%). In each region, area is expressed as a score of 0 (nothing),1 (1-9%),2 (10-29%),3 (30-49%),4 (50-69%),5 (70-89%) or 6 (90-100%). Within each area, tdegree of severity for erythema, induration and scaling are estimated between 0 and 4 (highest severity). The final score combines disease severity and effected BSA from for 4 regions using the formula PASI=0.1Ah(Eh+Ih+Sh)+ 0.2Au(Eu+Iu+Su)+0.3At(Et+It+St)+0.4Al(El+Il+Sl) where A=Area Score; E=erythema; I=induration; S=scaling;h=head; u=upper limbs;t=trunk;l=lower limbs. Efficacy analysis set (EAS): all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic.

End point type	Primary

End point timeframe:

Baseline, Week 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	37	37	36
Units: Unit on a scale				
least squares mean (standard error)	-1.6 (± 0.46)	-2.2 (± 0.46)	-1.4 (± 0.46)	-2.2 (± 0.46)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	35
Units: Unit on a scale				
least squares mean (standard error)	-2.4 (± 0.45)	-2.2 (± 0.42)	-2.5 (± 0.53)	-3.0 (± 0.51)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Unit on a scale				
least squares mean (standard error)	-2.8 (± 0.48)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1641 [1]
Method	ANCOVA
Parameter estimate	Least square (LS) mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.71
upper limit	0.43
Variability estimate	Standard error of the mean
Dispersion value	0.65

Notes:

[1] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.61 [2]
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.89
upper limit	1.26
Variability estimate	Standard error of the mean
Dispersion value	0.65

Notes:

[2] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1686 [3]
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.7
upper limit	0.45

Variability estimate	Standard error of the mean
Dispersion value	0.65

Notes:

[3] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1051 [4]
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.87
upper limit	0.25
Variability estimate	Standard error of the mean
Dispersion value	0.64

Notes:

[4] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3583 [5]
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.37
upper limit	0.88
Variability estimate	Standard error of the mean
Dispersion value	0.68

Notes:

[5] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1131 [6]
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.88
upper limit	0.29
Variability estimate	Standard error of the mean
Dispersion value	0.66

Notes:

[6] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1812 [7]
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.64
upper limit	0.47
Variability estimate	Standard error of the mean
Dispersion value	0.64

Notes:

[7] - Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.

Secondary: Percentage of Subjects With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

End point title	Percentage of Subjects With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

End point description:

PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed (N)=subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:
Baseline, Week 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	29	26	29
Units: Percentage of subjects				
number (confidence interval 90%)	6.9 (1.8 to 20.0)	10.3 (3.9 to 22.9)	15.4 (6.9 to 29.9)	10.3 (3.9 to 22.9)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	34	24	29
Units: Percentage of subjects				
number (confidence interval 90%)	21.4 (9.8 to 36.6)	14.7 (7.3 to 26.9)	20.8 (10.5 to 37.0)	27.6 (14.5 to 42.5)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: Percentage of subjects				
number (confidence interval 90%)	17.9 (8.9 to 33.3)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	58
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3747
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.6
upper limit	17.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.243
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	8.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.6
upper limit	25.9

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	58
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3747
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.6
upper limit	17.9

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0665
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	14.5

Confidence interval	
level	Other: 0.07 %
sides	2-sided
lower limit	-1.3
upper limit	31.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	58
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3423
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	6.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.1
upper limit	25.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1271
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	12.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.7
upper limit	30.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.401
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.2
upper limit	21.1

Secondary: Percentage of Subjects With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

End point title	Percentage of Subjects With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

End point description:

PASI score (0-72, higher score = greater severity) measured severity and extent of psoriasis. The 4 regions of the body parts are head (10%),arms (20%),trunk (30%) and legs (40%). In each region, area is expressed as a score of 0 (nothing),1 (1-9%),2 (10-29%),3 (30-49%),4 (50-69%),5 (70-89%) or 6 (90-100%). Within each area, tdegree of severity for erythema, induration and scaling are estimated between 0 and 4 (highest severity). The final score combines disease severity and effected BSA from for 4 regions using the formula PASI=0.1Ah(Eh+Ih+Sh)+ 0.2Au(Eu+Iu+Su)+0.3At(Et+It+St)+0.4Al(El+Il+Sl) where A=Area Score; E=erythema; I=induration; S=scaling;h=head; u=upper limbs;t=trunk;l=lower limbs. EAS: all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. N=subjects evaluable for this endpoint; n=subjects evaluable for the

End point type	Secondary

End point timeframe:

Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	36	34	35
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=32, 33, 34, 35, 35, 45, 32, 34, 37)	3.1 (0.3 to 13.1)	3.0 (0.3 to 12.7)	0 (0.0 to 8.0)	0 (0.0 to 7.7)
Week 2 (n=32, 36, 31, 35, 35, 45, 35, 32, 35)	3.1 (0.3 to 13.1)	0 (0.0 to 7.5)	0 (0.0 to 8.8)	2.9 (0.3 to 11.9)
week 4 (n=32, 32, 28, 34, 34, 45, 30, 33, 33)	3.1 (0.3 to 13.1)	0 (0.0 to 8.5)	3.6 (0.4 to 15.1)	0 (0.0 to 8.0)
Week 6 (n=31, 31, 27, 31, 29, 36, 28, 28, 29)	3.2 (0.3 to 13.5)	0 (0.0 to 8.8)	7.4 (2.0 to 20.4)	6.5 (1.7 to 18.7)
Week 8 (n=30, 30, 27, 31, 28, 36, 25, 29, 28)	6.7 (1.8 to 19.3)	6.7 (1.8 to 19.3)	7.4 (2.0 to 20.4)	6.5 (1.7 to 18.7)
Week 10 (29, 30, 25, 29, 28, 33, 24, 28, 26)	10.3 (3.9 to 22.9)	3.3 (0.4 to 14.0)	8.0 (2.1 to 21.4)	17.2 (8.6 to 32.0)
Week 12 (n=29, 29, 26, 29, 28, 34, 24, 29, 28)	10.3 (3.9 to 22.9)	10.3 (3.9 to 22.9)	7.7 (2.1 to 20.9)	20.7 (9.4 to 35.2)

Week 14 (n=29, 26, 23, 28, 28, 29, 23, 25, 27)	3.4 (0.4 to 14.5)	7.7 (2.1 to 20.9)	8.7 (2.3 to 22.8)	21.4 (9.8 to 36.6)
Week 16 (n=29, 27, 23, 28, 26, 31, 23, 24, 26)	3.4 (0.4 to 14.5)	11.1 (4.2 to 24.8)	17.4 (7.8 to 33.5)	25.0 (13.9 to 40.0)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	45	35	34
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=32, 33, 34, 35, 35, 45, 32, 34, 37)	0 (0.0 to 7.7)	0 (0.0 to 6.0)	0 (0.0 to 8.5)	2.9 (0.3 to 12.3)
Week 2 (n=32, 36, 31, 35, 35, 45, 35, 32, 35)	0 (0.0 to 7.7)	2.2 (0.2 to 9.2)	0 (0.0 to 7.7)	6.3 (1.7 to 18.0)
week 4 (n=32, 32, 28, 34, 34, 45, 30, 33, 33)	0 (0.0 to 8.0)	8.9 (3.9 to 18.0)	6.7 (1.8 to 19.3)	3.0 (0.3 to 12.7)
Week 6 (n=31, 31, 27, 31, 29, 36, 28, 28, 29)	10.3 (3.9 to 22.9)	13.9 (6.9 to 25.4)	10.7 (4.0 to 23.8)	10.7 (4.0 to 23.8)
Week 8 (n=30, 30, 27, 31, 28, 36, 25, 29, 28)	14.3 (6.4 to 28.4)	13.9 (6.9 to 25.4)	16.0 (7.2 to 30.7)	13.8 (6.2 to 27.9)
Week 10 (29, 30, 25, 29, 28, 33, 24, 28, 26)	14.3 (6.4 to 28.4)	18.2 (8.2 to 31.3)	20.8 (10.5 to 37.0)	10.7 (4.0 to 23.8)
Week 12 (n=29, 29, 26, 29, 28, 34, 24, 29, 28)	17.9 (8.9 to 33.3)	20.6 (11.3 to 34.9)	12.5 (4.7 to 28.2)	24.1 (13.4 to 38.5)
Week 14 (n=29, 26, 23, 28, 28, 29, 23, 25, 27)	14.3 (6.4 to 28.4)	10.3 (3.9 to 22.9)	13.0 (4.9 to 29.6)	20.0 (10.1 to 36.2)
Week 16 (n=29, 27, 23, 28, 26, 31, 23, 24, 26)	15.4 (6.9 to 29.9)	16.1 (8.1 to 29.7)	13.0 (4.9 to 29.6)	12.5 (4.7 to 28.2)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	37			
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=32, 33, 34, 35, 35, 45, 32, 34, 37)	2.7 (0.3 to 11.2)			
Week 2 (n=32, 36, 31, 35, 35, 45, 35, 32, 35)	5.7 (1.5 to 16.4)			
week 4 (n=32, 32, 28, 34, 34, 45, 30, 33, 33)	12.1 (5.4 to 25.1)			
Week 6 (n=31, 31, 27, 31, 29, 36, 28, 28, 29)	10.3 (3.9 to 22.9)			
Week 8 (n=30, 30, 27, 31, 28, 36, 25, 29, 28)	14.3 (6.4 to 28.4)			
Week 10 (29, 30, 25, 29, 28, 33, 24, 28, 26)	15.4 (6.9 to 29.9)			
Week 12 (n=29, 29, 26, 29, 28, 34, 24, 29, 28)	17.9 (8.9 to 33.3)			
Week 14 (n=29, 26, 23, 28, 28, 29, 23, 25, 27)	14.8 (6.6 to 29.1)			

Week 16 (n=29, 27, 23, 28, 26, 31, 23, 24, 26)	15.4 (6.9 to 29.9)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4225
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.2
upper limit	10.4

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7483
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	5

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7539
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	4.8

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7539
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	4.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.4
upper limit	8.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2125
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.4
upper limit	13.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2267
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.5
upper limit	12.2

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7592
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	4.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7299
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	5.5

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4463
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.3
upper limit	9.4

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7539
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	4.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7009
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.1
upper limit	5.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2507
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.5
upper limit	15.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2993
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.8
upper limit	14.3

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7363
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	5.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5369
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.5
upper limit	12.3

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7483
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.599
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.7
upper limit	11.6

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7483
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7926
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-5.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.4
upper limit	4.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3402
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9
upper limit	17.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3009
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.4
upper limit	17.7

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7364
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.4
upper limit	5.7

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.34
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.1
upper limit	15.9

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1631
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.8
upper limit	21.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6214
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.8
upper limit	13

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6214
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.8
upper limit	13

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6413
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.9
upper limit	11.7

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.1
upper limit	13.1

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5134
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.6
upper limit	15.2

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4468
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.4
upper limit	12.5

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2778
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.8
upper limit	23.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4571
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.5
upper limit	21

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5153
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.8
upper limit	16.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4741
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-15.3
upper limit	16.7

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8287
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21.1
upper limit	5.3

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5675
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.8
upper limit	14.2

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3792
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.8
upper limit	20.8

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2648
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	6.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.8
upper limit	23.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4438
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.3
upper limit	23.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7014
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-7.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-23.3
upper limit	9.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5841
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.7
upper limit	15

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-15.3
upper limit	15.3

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5834
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.5
upper limit	12.3

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1534
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.4
upper limit	27.2

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.272
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.8
upper limit	24.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 12	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6815
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-8.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.1
upper limit	10.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 12	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.39
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.4
upper limit	22

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 12	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5865
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20
upper limit	15.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3087
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.2
upper limit	18.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3137
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.2
upper limit	20.9

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0245
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	18
Confidence interval	
level	90 %
sides	2-sided
lower limit	2.7
upper limit	34.8

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1119
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3
upper limit	26

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.414
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.2
upper limit	20.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3638
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.5
upper limit	21.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1613
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.2
upper limit	22.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0557
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	13.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.5
upper limit	31.4

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0114
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	21.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.6
upper limit	38.3

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0753
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	11.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.8
upper limit	28.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5635
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.1
upper limit	15.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6201
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.3
upper limit	14.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4792
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.6
upper limit	17

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2356
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	9.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.2
upper limit	28.5

Secondary: Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

End point title	Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

End point description:

PASI score (0-72, higher score = greater severity) measured severity and extent of psoriasis. The 4 regions of the body parts are head (10%),arms (20%),trunk (30%) and legs (40%). In each region, area is expressed as a score of 0 (nothing),1 (1-9%),2 (10-29%),3 (30-49%),4 (50-69%),5 (70-89%) or 6 (90-100%). Within each area, tdegree of severity for erythema, induration and scaling are estimated between 0 and 4 (highest severity). The final score combines disease severity and effected BSA from for 4 regions using the formula PASI=0.1Ah(Eh+Ih+Sh)+ 0.2Au(Eu+Iu+Su)+0.3At(Et+It+St)+0.4Al(El+Il+Sl) where A=Area Score; E=erythema; I=induration; S=scaling;h=head; u=upper limbs;t=trunk;l=lower limbs. EAS: all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. N=subjects evaluable for this endpoint; n=subjects evaluable for the

End point type	Secondary

End point timeframe:

Baseline, Week (Wk) 1, 2, 4, 6, 8, 10 and 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	36	34	35
Units: Unit on a scale				
least squares mean (standard error)				
Change at Wk 1: n=32,33,34,35,35,45,32,34,37	-0.9 (± 0.22)	-0.7 (± 0.22)	-0.6 (± 0.22)	-0.9 (± 0.22)
Change at Wk 2: n=32,36,31,35,35,45,35,32,35	-1.4 (± 0.26)	-0.7 (± 0.26)	-0.9 (± 0.27)	-1.4 (± 0.26)
Change at Wk 4: n=32,32,28,34,34,45,30,33,33	-1.4 (± 0.31)	-1.2 (± 0.31)	-1.2 (± 0.33)	-1.4 (± 0.31)
Change at Wk 6: n=31,31,27,31,29,36,28,28,29	-1.5 (± 0.35)	-1.4 (± 0.35)	-1.2 (± 0.37)	-1.6 (± 0.35)
Change at Wk 8: n=30,30,27,31,28,36,25,29,28	-1.6 (± 0.39)	-1.9 (± 0.39)	-0.9 (± 0.41)	-2.1 (± 0.39)
Change at Wk 10: n=29,30,25,29,28,33,24,28,26	-1.6 (± 0.41)	-2.1 (± 0.40)	-1.6 (± 0.42)	-2.3 (± 0.40)
Change at Wk 12: n=29,29,26,29,28,34,24,29,28	-1.4 (± 0.49)	-2.1 (± 0.48)	-1.2 (± 0.51)	-2.2 (± 0.48)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	45	35	34
Units: Unit on a scale				
least squares mean (standard error)				
Change at Wk 1: n=32,33,34,35,35,45,32,34,37	-0.8 (± 0.22)	-0.5 (± 0.19)	-0.7 (± 0.23)	-0.7 (± 0.22)
Change at Wk 2: n=32,36,31,35,35,45,35,32,35	-1.3 (± 0.26)	-0.8 (± 0.25)	-1.4 (± 0.29)	-1.6 (± 0.29)
Change at Wk 4: n=32,32,28,34,34,45,30,33,33	-1.6 (± 0.31)	-1.0 (± 0.35)	-2.3 (± 0.42)	-1.7 (± 0.41)
Change at Wk 6: n=31,31,27,31,29,36,28,28,29	-2.4 (± 0.36)	-1.2 (± 0.37)	-2.5 (± 0.45)	-2.1 (± 0.44)
Change at Wk 8: n=30,30,27,31,28,36,25,29,28	-2.3 (± 0.40)	-1.3 (± 0.42)	-2.4 (± 0.50)	-2.3 (± 0.48)
Change at Wk 10: n=29,30,25,29,28,33,24,28,26	-2.4 (± 0.41)	-1.1 (± 0.46)	-2.4 (± 0.55)	-2.4 (± 0.53)
Change at Wk 12: n=29,29,26,29,28,34,24,29,28	-2.4 (± 0.49)	-0.9 (± 0.51)	-2.5 (± 0.62)	-2.5 (± 0.59)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	37			
Units: Unit on a scale				
least squares mean (standard error)				
Change at Wk 1: n=32,33,34,35,35,45,32,34,37	-0.8 (± 0.22)			
Change at Wk 2: n=32,36,31,35,35,45,35,32,35	-1.7 (± 0.29)			
Change at Wk 4: n=32,32,28,34,34,45,30,33,33	-2.2 (± 0.41)			
Change at Wk 6: n=31,31,27,31,29,36,28,28,29	-2.1 (± 0.43)			
Change at Wk 8: n=30,30,27,31,28,36,25,29,28	-2.5 (± 0.48)			
Change at Wk 10: n=29,30,25,29,28,33,24,28,26	-2.4 (± 0.53)			
Change at Wk 12: n=29,29,26,29,28,34,24,29,28	-2.3 (± 0.59)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 1: Mixed-effect model with repeated measures (MMRM) analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured

covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8038
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.25
upper limit	0.79
Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8267
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.22
upper limit	0.81
Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6039
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.43
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6339
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.41
upper limit	0.62
Variability estimate	Standard error of the mean
Dispersion value	0.31

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2666
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.68
upper limit	0.31
Variability estimate	Standard error of the mean
Dispersion value	0.3

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2257
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	0.26
Variability estimate	Standard error of the mean
Dispersion value	0.29

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1306
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.81
upper limit	0.15
Variability estimate	Standard error of the mean
Dispersion value	0.29

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9704
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.09
upper limit	1.31
Variability estimate	Standard error of the mean
Dispersion value	0.37

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.889
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.16
upper limit	1.09
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4506
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.66
upper limit	0.57
Variability estimate	Standard error of the mean
Dispersion value	0.37

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.584
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.53
upper limit	0.69
Variability estimate	Standard error of the mean
Dispersion value	0.37

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0769
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.17
upper limit	0.08
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0242
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.39
upper limit	-0.13
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0127
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.49
upper limit	-0.23
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6693
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.54
upper limit	0.93
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6742
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.55
upper limit	0.96
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4486
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.79
upper limit	0.67
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3219
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.93
upper limit	0.53
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0096
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.21
upper limit	-0.39
Variability estimate	Standard error of the mean
Dispersion value	0.55

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0862
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.64
upper limit	0.15
Variability estimate	Standard error of the mean
Dispersion value	0.54

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0111
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.15
upper limit	-0.36
Variability estimate	Standard error of the mean
Dispersion value	0.54

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6107
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.68
upper limit	0.97
Variability estimate	Standard error of the mean
Dispersion value	0.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.724
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.3

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.54
upper limit	1.15
Variability estimate	Standard error of the mean
Dispersion value	0.51

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.43
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.91
upper limit	0.74
Variability estimate	Standard error of the mean
Dispersion value	0.5

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0501
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.66
upper limit	0
Variability estimate	Standard error of the mean
Dispersion value	0.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0157
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.23
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	0.58

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0645
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.83
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.57

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0621
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.84
upper limit	0.06
Variability estimate	Standard error of the mean
Dispersion value	0.57

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2959
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.21
upper limit	0.62
Variability estimate	Standard error of the mean
Dispersion value	0.55

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD

Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9043
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.19
upper limit	1.69
Variability estimate	Standard error of the mean
Dispersion value	0.57

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2014
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.38
upper limit	0.45
Variability estimate	Standard error of the mean
Dispersion value	0.55

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0948
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.66
upper limit	0.19
Variability estimate	Standard error of the mean
Dispersion value	0.56

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0416
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.21
upper limit	-0.06
Variability estimate	Standard error of the mean
Dispersion value	0.65

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0454
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.14
upper limit	-0.03
Variability estimate	Standard error of the mean
Dispersion value	0.64

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0256
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.31
upper limit	-0.2
Variability estimate	Standard error of the mean
Dispersion value	0.64

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2326
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.36
upper limit	0.53
Variability estimate	Standard error of the mean
Dispersion value	0.57

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5141
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.95
upper limit	0.99
Variability estimate	Standard error of the mean
Dispersion value	0.59

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1124
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.64
upper limit	0.25
Variability estimate	Standard error of the mean
Dispersion value	0.57

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0983
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.7
upper limit	0.21
Variability estimate	Standard error of the mean
Dispersion value	0.58

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0412
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.46
upper limit	-0.07
Variability estimate	Standard error of the mean
Dispersion value	0.72

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.034
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3

Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.47
upper limit	-0.13
Variability estimate	Standard error of the mean
Dispersion value	0.71

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0379
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.44
upper limit	-0.09
Variability estimate	Standard error of the mean
Dispersion value	0.71

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1291
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.91
upper limit	0.36
Variability estimate	Standard error of the mean
Dispersion value	0.68

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5776
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.03
upper limit	1.3
Variability estimate	Standard error of the mean
Dispersion value	0.7

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1044
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2
upper limit	0.27
Variability estimate	Standard error of the mean
Dispersion value	0.69

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0608
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.23
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.69

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0309
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.84
upper limit	-0.18
Variability estimate	Standard error of the mean
Dispersion value	0.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0242
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.85
upper limit	-0.26
Variability estimate	Standard error of the mean
Dispersion value	0.78

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0394
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.69
upper limit	-0.09
Variability estimate	Standard error of the mean
Dispersion value	0.78

Secondary: Change From Baseline in PASI Scores at Week 14 and 16

End point title	Change From Baseline in PASI Scores at Week 14 and 16

End point description:

PASI score (0-72, higher score = greater severity) measured severity and extent of psoriasis. The 4 regions of the body parts are head (10%),arms (20%),trunk (30%) and legs (40%). In each region, area is expressed as a score of 0 (nothing),1 (1-9%),2 (10-29%),3 (30-49%),4 (50-69%),5 (70-89%) or 6 (90-100%). Within each area, tdegree of severity for erythema, induration and scaling are estimated between 0 and 4 (highest severity). The final score combines disease severity and effected BSA from for 4 regions using the formula PASI=0.1Ah(Eh+Ih+Sh)+ 0.2Au(Eu+Iu+Su)+0.3At(Et+It+St)+0.4Al(El+Il+Sl) where A=Area Score; E=erythema; I=induration; S=scaling;h=head; u=upper limbs;t=trunk;l=lower limbs. EAS: all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:
Baseline, Wk 14 and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	37	37	36
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline: n=36,37,37,36,37,49,36,35,38	6.12 (± 2.870)	7.19 (± 3.370)	6.46 (± 2.932)	6.63 (± 3.468)
Change at Wk 14: n=29,26,23,28,28,29,23,25,27	-0.83 (± 2.379)	-2.24 (± 2.945)	-0.72 (± 4.107)	-1.81 (± 3.228)
Change at Wk 16: n=29,27,23,28,26,31,23,24,26)	-0.46 (± 2.603)	-2.06 (± 3.252)	-0.78 (± 4.223)	-2.10 (± 3.666)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	35
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline: n=36,37,37,36,37,49,36,35,38	6.83 (± 3.137)	6.08 (± 2.558)	7.07 (± 3.579)	5.80 (± 2.765)
Change at Wk 14: n=29,26,23,28,28,29,23,25,27	-1.87 (± 2.942)	-0.82 (± 3.581)	-1.04 (± 3.732)	-2.06 (± 3.343)
Change at Wk 16: n=29,27,23,28,26,31,23,24,26)	-1.68 (± 3.255)	-0.67 (± 4.008)	-0.71 (± 3.455)	-1.75 (± 3.887)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline: n=36,37,37,36,37,49,36,35,38	7.94 (± 4.071)			
Change at Wk 14: n=29,26,23,28,28,29,23,25,27	-1.19 (± 3.323)			
Change at Wk 16: n=29,27,23,28,26,31,23,24,26)	-1.03 (± 3.351)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

End point title	Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

End point description:

PASI score (0-72, higher score = greater severity) measured severity and extent of psoriasis. The 4 regions of the body parts are head (10%),arms (20%),trunk (30%) and legs (40%). In each region, area is expressed as a score of 0 (nothing),1 (1-9%),2 (10-29%),3 (30-49%),4 (50-69%),5 (70-89%) or 6 (90-100%). Within each area, tdegree of severity for erythema, induration and scaling are estimated between 0 and 4 (highest severity). The final score combines disease severity and effected BSA from for 4 regions using the formula PASI=0.1Ah(Eh+Ih+Sh)+ 0.2Au(Eu+Iu+Su)+0.3At(Et+It+St)+0.4Al(El+Il+Sl) where A=Area Score; E=erythema; I=induration; S=scaling;h=head; u=upper limbs;t=trunk;l=lower limbs. EAS: all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. N=subjects evaluable for this endpoint; n=subjects evaluable for the

End point type	Secondary

End point timeframe:

Baseline, Wk 1, 2, 4, 6, 8, 10 and 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	36	34	35
Units: Percent change				
least squares mean (standard error)				
Change at Wk 1: n=32,33,34,35,35,45,32,34,37	-15.5 (± 3.62)	-12.9 (± 3.57)	-8.2 (± 3.56)	-10.4 (± 3.49)
Change at Wk 2: n=32,36,31,35,35,45,35,32,35)	-21.6 (± 4.25)	-12.4 (± 4.10)	-12.6 (± 4.34)	-17.9 (± 4.13)
Change at Wk 4: n=32,32,28,34,34,45,30,33,33)	-24.1 (± 4.69)	-20.5 (± 4.65)	-15.6 (± 4.90)	-17.6 (± 4.59)
Change at Wk 6: n=31,31,27,31,29,36,28,28,29	-23.7 (± 5.88)	-20.3 (± 5.83)	-18.4 (± 6.18)	-21.8 (± 5.83)
Change at Wk 8: n=30,30,27,31,28,36,25,29,28)	-25.3 (± 6.48)	-25.6 (± 6.44)	-14.3 (± 6.78)	-30.5 (± 6.41)
Change at Wk 10: n=29,30,25,29,28,33,24,28,26	-26.8 (± 6.42)	-27.6 (± 6.34)	-22.9 (± 6.73)	-35.3 (± 6.36)
Change at Wk 12: n=29,29,26,29,28,34,24,29,28	-20.0 (± 7.36)	-29.1 (± 7.30)	-18.5 (± 7.70)	-33.7 (± 7.30)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	45	35	34
Units: Percent change				
least squares mean (standard error)				
Change at Wk 1: n=32,33,34,35,35,45,32,34,37	-13.0 (± 3.51)	-7.4 (± 3.10)	-9.0 (± 3.64)	-13.7 (± 3.58)
Change at Wk 2: n=32,36,31,35,35,45,35,32,35)	-19.8 (± 4.14)	-11.7 (± 3.99)	-20.7 (± 4.60)	-23.3 (± 4.68)

Change at Wk 4: n=32,32,28,34,34,45,30,33,33)	-25.1 (± 4.61)	-13.2 (± 5.69)	-33.9 (± 6.85)	-24.1 (± 6.66)
Change at Wk 6: n=31,31,27,31,29,36,28,28,29	-36.0 (± 5.92)	-17.8 (± 6.10)	-36.6 (± 7.31)	-31.2 (± 7.12)
Change at Wk 8: n=30,30,27,31,28,36,25,29,28)	-35.9 (± 6.57)	-18.1 (± 6.70)	-35.2 (± 8.07)	-32.4 (± 7.76)
Change at Wk 10: n=29,30,25,29,28,33,24,28,26	-36.1 (± 6.48)	-12.5 (± 7.62)	-33.4 (± 9.12)	-35.1 (± 8.75)
Change at Wk 12: n=29,29,26,29,28,34,24,29,28	-39.0 (± 7.47)	-9.6 (± 8.61)	-34.1 (± 10.35)	-35.7 (± 9.84)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	37			
Units: Percent change				
least squares mean (standard error)				
Change at Wk 1: n=32,33,34,35,35,45,32,34,37	-13.5 (± 3.52)			
Change at Wk 2: n=32,36,31,35,35,45,35,32,35)	-24.7 (± 4.58)			
Change at Wk 4: n=32,32,28,34,34,45,30,33,33)	-29.2 (± 6.64)			
Change at Wk 6: n=31,31,27,31,29,36,28,28,29	-27.5 (± 7.08)			
Change at Wk 8: n=30,30,27,31,28,36,25,29,28)	-34.3 (± 7.76)			
Change at Wk 10: n=29,30,25,29,28,33,24,28,26	-34.6 (± 8.77)			
Change at Wk 12: n=29,29,26,29,28,34,24,29,28	33.7 (± 9.88)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6917
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	2.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.86
upper limit	10.97

Variability estimate	Standard error of the mean
Dispersion value	5.09

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9241
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	7.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.09
upper limit	15.69
Variability estimate	Standard error of the mean
Dispersion value	5.07

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8443
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	5.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.21
upper limit	13.42
Variability estimate	Standard error of the mean
Dispersion value	5.03

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6911
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	2.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.82
upper limit	10.86
Variability estimate	Standard error of the mean
Dispersion value	5.04

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3676
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.56
upper limit	6.31
Variability estimate	Standard error of the mean
Dispersion value	4.79

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 1: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0915
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-6.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.13
upper limit	1.5
Variability estimate	Standard error of the mean
Dispersion value	4.72

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.097
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-6.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.96
upper limit	1.65
Variability estimate	Standard error of the mean
Dispersion value	4.72

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9389
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	9.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.59
upper limit	18.97
Variability estimate	Standard error of the mean
Dispersion value	5.91

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9295
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.06
upper limit	19.02
Variability estimate	Standard error of the mean
Dispersion value	6.07

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7308
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	3.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.15
upper limit	13.45
Variability estimate	Standard error of the mean
Dispersion value	5.92

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6199
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	1.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.01
upper limit	11.64
Variability estimate	Standard error of the mean
Dispersion value	5.94

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0699
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.13
upper limit	1.04
Variability estimate	Standard error of the mean
Dispersion value	6.09

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.03
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-11.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21.79
upper limit	-1.48
Variability estimate	Standard error of the mean
Dispersion value	6.14

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0168
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-13.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-23.15
upper limit	-2.98
Variability estimate	Standard error of the mean
Dispersion value	6.09

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7083
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	3.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.3
upper limit	14.57
Variability estimate	Standard error of the mean
Dispersion value	6.61

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8955
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	8.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.66
upper limit	19.75
Variability estimate	Standard error of the mean
Dispersion value	6.77

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8386
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	6.5

Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.35
upper limit	17.37
Variability estimate	Standard error of the mean
Dispersion value	6.56

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4371
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.93
upper limit	9.84
Variability estimate	Standard error of the mean
Dispersion value	6.58

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0108
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-20.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-35.42
upper limit	-5.92
Variability estimate	Standard error of the mean
Dispersion value	8.91

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1066
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-10.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.43
upper limit	3.55
Variability estimate	Standard error of the mean
Dispersion value	8.75

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0344
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-16
Confidence interval	
level	90 %
sides	2-sided
lower limit	-30.54
upper limit	-1.55
Variability estimate	Standard error of the mean
Dispersion value	8.76

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6594
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	3.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.3
upper limit	17.13
Variability estimate	Standard error of the mean
Dispersion value	8.29

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7307
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	5.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.85
upper limit	19.36
Variability estimate	Standard error of the mean
Dispersion value	8.52

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5914
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	1.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.78
upper limit	15.61
Variability estimate	Standard error of the mean
Dispersion value	8.28

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0709
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-12.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-26.13
upper limit	1.49
Variability estimate	Standard error of the mean
Dispersion value	8.34

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0253
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-18.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.55
upper limit	-3.01
Variability estimate	Standard error of the mean
Dispersion value	9.53

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.078
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-13.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-28.89
upper limit	2.15
Variability estimate	Standard error of the mean
Dispersion value	9.38

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1516
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-9.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.17
upper limit	5.83
Variability estimate	Standard error of the mean
Dispersion value	9.36

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4861
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-15.45
upper limit	14.81
Variability estimate	Standard error of the mean
Dispersion value	9.14

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8795
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	11
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.48
upper limit	26.55
Variability estimate	Standard error of the mean
Dispersion value	9.38

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2867
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-5.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.22
upper limit	9.94
Variability estimate	Standard error of the mean
Dispersion value	9.11

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1267
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-10.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.86
upper limit	4.69
Variability estimate	Standard error of the mean
Dispersion value	9.23

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0526
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-17.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.48
upper limit	0.26
Variability estimate	Standard error of the mean
Dispersion value	10.49

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0827
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-14.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-31.26
upper limit	2.68
Variability estimate	Standard error of the mean
Dispersion value	10.25

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0592
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-16.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	-33.12
upper limit	0.86
Variability estimate	Standard error of the mean
Dispersion value	10.26

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4657
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-15.72
upper limit	14.16
Variability estimate	Standard error of the mean
Dispersion value	9.03

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6612
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	3.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.52
upper limit	19.26
Variability estimate	Standard error of the mean
Dispersion value	9.3

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1749
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-8.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-23.42
upper limit	6.48
Variability estimate	Standard error of the mean
Dispersion value	9.03

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1548
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-9.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-24.39
upper limit	5.8
Variability estimate	Standard error of the mean
Dispersion value	9.12

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.04
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-21
Confidence interval	
level	90 %
sides	2-sided
lower limit	-40.67
upper limit	-1.28
Variability estimate	Standard error of the mean
Dispersion value	11.89

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0267
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-22.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-41.82
upper limit	-3.39
Variability estimate	Standard error of the mean
Dispersion value	11.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0295
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-22.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-41.42
upper limit	-2.89
Variability estimate	Standard error of the mean
Dispersion value	11.63

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1903
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-9.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-26.3
upper limit	8.05
Variability estimate	Standard error of the mean
Dispersion value	10.38

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.553
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	1.4

Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.21
upper limit	19.06
Variability estimate	Standard error of the mean
Dispersion value	10.65

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0933
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-13.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-30.92
upper limit	3.4
Variability estimate	Standard error of the mean
Dispersion value	10.37

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.036
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-19
Confidence interval	
level	90 %
sides	2-sided
lower limit	-36.37
upper limit	-1.65
Variability estimate	Standard error of the mean
Dispersion value	10.49

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0354
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-24.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-46.85
upper limit	-2.23
Variability estimate	Standard error of the mean
Dispersion value	13.46

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0239
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-26.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-47.77
upper limit	-4.46
Variability estimate	Standard error of the mean
Dispersion value	13.07

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0342
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-24.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-45.84
upper limit	-2.38
Variability estimate	Standard error of the mean
Dispersion value	13.11

Secondary: Percent Change From Baseline in PASI Scores at Week 14 and 16

End point title	Percent Change From Baseline in PASI Scores at Week 14 and 16

End point description:

PASI score (0-72, higher score = greater severity) measured severity and extent of psoriasis. The 4 regions of the body parts are head (10%),arms (20%),trunk (30%) and legs (40%). In each region, area is expressed as a score of 0 (nothing),1 (1-9%),2 (10-29%),3 (30-49%),4 (50-69%),5 (70-89%) or 6 (90-100%). Within each area, tdegree of severity for erythema, induration and scaling are estimated between 0 and 4 (highest severity). The final score combines disease severity and effected BSA from for 4 regions using the formula PASI=0.1Ah(Eh+Ih+Sh)+ 0.2Au(Eu+Iu+Su)+0.3At(Et+It+St)+0.4Al(El+Il+Sl) where A=Area Score; E=erythema; I=induration; S=scaling;h=head; u=upper limbs;t=trunk;l=lower limbs. EAS: all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Wk 14 and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	37	37	36
Units: Percent change				
arithmetic mean (standard deviation)				
Baseline: n=36,37,37,36,37,49,36,35,38	6.12 (± 2.870)	7.19 (± 3.370)	6.46 (± 2.932)	6.63 (± 3.468)
Change at Wk 14: n=29,26,23,28,28,29,23,25,27	-12.76 (± 49.660)	-25.94 (± 40.339)	-8.58 (± 59.407)	-23.14 (± 47.501)
Change at Wk 16: n=29,27,23,28,26,31,23,24,26	-4.72 (± 56.401)	-23.01 (± 44.766)	-9.00 (± 60.088)	-29.24 (± 52.608)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	35
Units: Percent change				
arithmetic mean (standard deviation)				
Baseline: n=36,37,37,36,37,49,36,35,38	6.83 (± 3.137)	6.08 (± 2.558)	7.07 (± 3.579)	5.80 (± 2.765)
Change at Wk 14: n=29,26,23,28,28,29,23,25,27	-30.07 (± 40.222)	-5.74 (± 74.846)	-14.18 (± 58.599)	-27.56 (± 45.370)
Change at Wk 16: n=29,27,23,28,26,31,23,24,26	-27.17 (± 41.153)	-3.75 (± 83.415)	-9.99 (± 60.306)	-24.09 (± 48.685)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Percent change				
arithmetic mean (standard deviation)				
Baseline: n=36,37,37,36,37,49,36,35,38	7.94 (± 4.071)			
Change at Wk 14: n=29,26,23,28,28,29,23,25,27	-19.74 (± 49.727)			
Change at Wk 16: n=29,27,23,28,26,31,23,24,26	-21.12 (± 52.521)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12

End point title	Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12

End point description:

Subjects were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 1, 2, 4, 6, 8, 10 and 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	36	34	36
Units: Unit on a scale				
least squares mean (standard error)				
Baseline (n=33, 34, 33, 29, 36, 43, 33, 32, 30)	4.6 (± 0.31)	4.4 (± 0.30)	4.5 (± 0.31)	4.1 (± 0.33)
Week 1 (n=35, 36, 34, 36, 36, 47, 34, 34, 29)	4.1 (± 0.31)	3.9 (± 0.30)	3.6 (± 0.31)	3.5 (± 0.33)
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	3.6 (± 0.31)	3.5 (± 0.31)	3.3 (± 0.31)	3.2 (± 0.33)
Week 4 (n=31, 31, 27, 33, 34, 45, 29, 31, 31)	3.5 (± 0.32)	3.7 (± 0.32)	3.2 (± 0.33)	3.2 (± 0.34)
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	3.5 (± 0.32)	4.0 (± 0.32)	3.5 (± 0.34)	3.2 (± 0.34)
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 27, 27)	3.1 (± 0.32)	3.4 (± 0.32)	3.2 (± 0.33)	3.1 (± 0.34)
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	3.3 (± 0.33)	3.0 (± 0.33)	3.0 (± 0.34)	3.1 (± 0.35)
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	3.4 (± 0.33)	3.1 (± 0.33)	3.1 (± 0.33)	3.0 (± 0.35)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	48	35	35
Units: Unit on a scale				
least squares mean (standard error)				
Baseline (n=33, 34, 33, 29, 36, 43, 33, 32, 30)	4.5 (± 0.29)	4.9 (± 0.28)	4.8 (± 0.32)	4.4 (± 0.32)
Week 1 (n=35, 36, 34, 36, 36, 47, 34, 34, 29)	3.6 (± 0.30)	4.0 (± 0.28)	3.8 (± 0.32)	3.4 (± 0.32)
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	3.5 (± 0.30)	3.5 (± 0.28)	3.6 (± 0.32)	2.9 (± 0.32)
Week 4 (n=31, 31, 27, 33, 34, 45, 29, 31, 31)	3.2 (± 0.30)	3.4 (± 0.29)	3.0 (± 0.34)	3.0 (± 0.34)
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	2.9 (± 0.32)	3.6 (± 0.31)	2.8 (± 0.35)	3.0 (± 0.35)
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 27, 27)	2.8 (± 0.32)	3.3 (± 0.32)	2.7 (± 0.37)	2.9 (± 0.35)
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	2.3 (± 0.32)	4.1 (± 0.33)	2.8 (± 0.36)	2.9 (± 0.35)
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	2.6 (± 0.32)	4.0 (± 0.32)	2.7 (± 0.37)	3.0 (± 0.35)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	31			
Units: Unit on a scale				
least squares mean (standard error)				

Baseline (n=33, 34, 33, 29, 36, 43, 33, 32, 30)	5.4 (± 0.34)			
Week 1 (n=35, 36, 34, 36, 36, 47, 34, 34, 29)	3.7 (± 0.35)			
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	3.4 (± 0.35)			
Week 4 (n=31, 31, 27, 33, 34, 45, 29, 31, 31)	3.4 (± 0.36)			
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	2.9 (± 0.38)			
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 27, 27)	2.7 (± 0.38)			
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	3.6 (± 0.39)			
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	3.2 (± 0.40)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3279
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.91
upper limit	0.52
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3566
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.88
upper limit	0.56
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1165
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.29
upper limit	0.21
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3633
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.85
upper limit	0.55
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3766
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.83
upper limit	0.56
Variability estimate	Standard error of the mean
Dispersion value	0.42

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1179
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.22
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8647
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.24
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3294
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.9
upper limit	0.52
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1231
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.23
upper limit	0.21
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0878
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.37
upper limit	0.13
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1225
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.2
upper limit	0.21
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3663
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.85
upper limit	0.56
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0929
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.27
upper limit	0.14
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3111
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.95
upper limit	0.51
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4745
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.74
upper limit	0.69
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2409
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.03
upper limit	0.42
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2018
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.13
upper limit	0.37
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3925
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.83
upper limit	0.59
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5348
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.66
upper limit	0.73
Variability estimate	Standard error of the mean
Dispersion value	0.42

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0739
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.33
upper limit	0.09
Variability estimate	Standard error of the mean
Dispersion value	0.43

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4014
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.84
upper limit	0.62
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6588
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.56
upper limit	0.93
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2997
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1
upper limit	0.52
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 4:MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2518
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.08
upper limit	0.46
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2634
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1
upper limit	0.45
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1999
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.11
upper limit	0.36
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1847
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.13
upper limit	0.33
Variability estimate	Standard error of the mean
Dispersion value	0.44

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4569
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.81
upper limit	0.71
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8536
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.27
upper limit	1.22
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 6:MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4812
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.79
upper limit	0.74
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2276
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.13
upper limit	0.42
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0895
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.34
upper limit	0.14
Variability estimate	Standard error of the mean
Dispersion value	0.45

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0411
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.58
upper limit	-0.04
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0928
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.4
upper limit	0.15
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0799
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.48
upper limit	0.12
Variability estimate	Standard error of the mean
Dispersion value	0.49

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7872
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.39
upper limit	1.11
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6294
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.61
upper limit	0.92
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5174
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.76
upper limit	0.8
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3136
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.98
upper limit	0.53
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.102
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.42
upper limit	0.18
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1923
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.2
upper limit	0.37
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0997
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.44
upper limit	0.18
Variability estimate	Standard error of the mean
Dispersion value	0.49

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2497
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.08
upper limit	0.45
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2568
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.08
upper limit	0.47
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.373
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.95
upper limit	0.64
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0137
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.76
upper limit	-0.26
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0055
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.06
upper limit	-0.44
Variability estimate	Standard error of the mean
Dispersion value	0.49

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0069
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.99
upper limit	-0.4
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1648
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.34
upper limit	0.34
Variability estimate	Standard error of the mean
Dispersion value	0.51

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2931
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.02
upper limit	0.51
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3047
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.01
upper limit	0.53
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1924
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.22
upper limit	0.38
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0465
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.52
upper limit	-0.02
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0048
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.08
upper limit	-0.47
Variability estimate	Standard error of the mean
Dispersion value	0.49

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0186
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.78
upper limit	-0.21
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0675
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.61
upper limit	0.08
Variability estimate	Standard error of the mean
Dispersion value	0.51

Secondary: Absolute PP-NRS Score at Week 14 and 16

End point title	Absolute PP-NRS Score at Week 14 and 16

End point description:

Subjects were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Week 14 and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	27	24	24
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 27)	5.2 (± 3.02)	2.6 (± 2.52)	2.8 (± 2.38)	2.4 (± 2.39)
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	4.9 (± 2.93)	3.2 (± 2.75)	3.1 (± 2.63)	2.5 (± 2.45)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	30	23	25
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 27)	3.2 (± 2.38)	4.0 (± 2.77)	3.5 (± 2.89)	2.8 (± 2.57)

Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	3.2 (± 2.42)	3.8 (± 2.69)	3.4 (± 2.77)	3.5 (± 2.91)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 27)	5.5 (± 2.81)			
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	5.8 (± 2.76)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12

End point title	Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12

End point description:

Subjects were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Wk 1, 2, 4, 6, 8, 10 and 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	33	34	32	29
Units: Unit on a scale				
least squares mean (standard error)				
Change at Wk 1: n=33,34,32,29,35,43,32,32,28)	-0.4 (± 0.23)	-0.6 (± 0.23)	-0.9 (± 0.23)	-0.9 (± 0.25)
Change at Wk 2: n=33,33,31,29,34,43,33,32,28	-0.9 (± 0.28)	-0.9 (± 0.27)	-1.1 (± 0.28)	-1.2 (± 0.30)
Change at Wk 4: n=29,28,26,27,33,40,27,28,25	-1.0 (± 0.33)	-0.8 (± 0.33)	-1.0 (± 0.34)	-1.2 (± 0.36)
Change at Wk 6: n=30,28,24,25,28,32,25,25,22	-0.9 (± 0.36)	-0.4 (± 0.36)	-1.0 (± 0.38)	-1.2 (± 0.39)
Change at Wk 8: n=28,28,25,25,26,30,22,25,22	-1.4 (± 0.38)	-1.1 (± 0.38)	-1.2 (± 0.39)	-1.3 (± 0.41)
Change at Wk 10: n=27,25,24,23,28,26,23,26,20	-1.1 (± 0.43)	-1.4 (± 0.44)	-1.3 (± 0.45)	-1.2 (± 0.46)

Change at Wk 12: n=27,26,25,23,27,28,22,26,19	-1.0 (± 0.42)	-1.3 (± 0.43)	-1.2 (± 0.44)	-1.3 (± 0.45)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	43	33	32
Units: Unit on a scale				
least squares mean (standard error)				
Change at Wk 1: n=33,34,32,29,35,43,32,32,28)	-0.9 (± 0.22)	-0.9 (± 0.24)	-1.0 (± 0.27)	-1.4 (± 0.28)
Change at Wk 2: n=33,33,31,29,34,43,33,32,28	-1.0 (± 0.27)	-1.3 (± 0.25)	-1.3 (± 0.29)	-1.9 (± 0.30)
Change at Wk 4: n=29,28,26,27,33,40,27,28,25	-1.2 (± 0.32)	-1.3 (± 0.32)	-1.7 (± 0.38)	-1.7 (± 0.38)
Change at Wk 6: n=30,28,24,25,28,32,25,25,22	-1.6 (± 0.36)	-1.1 (± 0.31)	-1.9 (± 0.36)	-1.8 (± 0.36)
Change at Wk 8: n=28,28,25,25,26,30,22,25,22	-1.6 (± 0.38)	-1.2 (± 0.38)	-2.2 (± 0.44)	-1.8 (± 0.43)
Change at Wk 10: n=27,25,24,23,28,26,23,26,20	-2.1 (± 0.42)	-0.5 (± 0.39)	-2.1 (± 0.44)	-1.9 (± 0.42)
Change at Wk 12: n=27,26,25,23,27,28,22,26,19	-1.8 (± 0.42)	-0.6 (± 0.41)	-2.3 (± 0.47)	-1.8 (± 0.44)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: Unit on a scale				
least squares mean (standard error)				
Change at Wk 1: n=33,34,32,29,35,43,32,32,28)	-1.2 (± 0.30)			
Change at Wk 2: n=33,33,31,29,34,43,33,32,28	-1.5 (± 0.32)			
Change at Wk 4: n=29,28,26,27,33,40,27,28,25	-1.6 (± 0.41)			
Change at Wk 6: n=30,28,24,25,28,32,25,25,22	-2.1 (± 0.39)			
Change at Wk 8: n=28,28,25,25,26,30,22,25,22	-2.2 (± 0.46)			
Change at Wk 10: n=27,25,24,23,28,26,23,26,20	-1.2 (± 0.47)			
Change at Wk 12: n=27,26,25,23,27,28,22,26,19	-1.5 (± 0.49)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3232
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.69
upper limit	0.39
Variability estimate	Standard error of the mean
Dispersion value	0.33

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0736
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.03
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.33

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0743
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.07
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.35

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0641
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.03
upper limit	0.04
Variability estimate	Standard error of the mean
Dispersion value	0.32

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3887
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.71
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.36

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0767
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.15
upper limit	0.08
Variability estimate	Standard error of the mean
Dispersion value	0.37

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2529
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.89
upper limit	0.38
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5304
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.61
upper limit	0.67
Variability estimate	Standard error of the mean
Dispersion value	0.39

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.292
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.87
upper limit	0.43
Variability estimate	Standard error of the mean
Dispersion value	0.39

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2593
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	0.57
Variability estimate	Standard error of the mean
Dispersion value	0.41

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.431
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	0.57
Variability estimate	Standard error of the mean
Dispersion value	0.38

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5477
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.59
upper limit	0.69
Variability estimate	Standard error of the mean
Dispersion value	0.39

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0696
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.24
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.39

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3583
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.82
upper limit	0.53
Variability estimate	Standard error of the mean
Dispersion value	0.41

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6826
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.56
upper limit	1.01
Variability estimate	Standard error of the mean
Dispersion value	0.47

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.457
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.84
upper limit	0.74
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3265
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.03
upper limit	0.59
Variability estimate	Standard error of the mean
Dispersion value	0.49

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3039
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1
upper limit	0.53
Variability estimate	Standard error of the mean
Dispersion value	0.46

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2086
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.23
upper limit	0.42
Variability estimate	Standard error of the mean
Dispersion value	0.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2172
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.22
upper limit	0.44
Variability estimate	Standard error of the mean
Dispersion value	0.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2855
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.16
upper limit	0.57
Variability estimate	Standard error of the mean
Dispersion value	0.52

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8372
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.34
upper limit	1.36
Variability estimate	Standard error of the mean
Dispersion value	0.51

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4792
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.89
upper limit	0.84
Variability estimate	Standard error of the mean
Dispersion value	0.52

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3331
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.12
upper limit	0.65
Variability estimate	Standard error of the mean
Dispersion value	0.53

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.108
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.47
upper limit	0.21
Variability estimate	Standard error of the mean
Dispersion value	0.51

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0455
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.61
upper limit	-0.02
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0761
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.49
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0273
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.8
upper limit	-0.14
Variability estimate	Standard error of the mean
Dispersion value	0.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7214
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.57
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.54

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD

Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6132
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.75
upper limit	1.06
Variability estimate	Standard error of the mean
Dispersion value	0.55

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5704
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.83
upper limit	1.02
Variability estimate	Standard error of the mean
Dispersion value	0.56

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3449
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.1
upper limit	0.67
Variability estimate	Standard error of the mean
Dispersion value	0.53

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0493
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.94
upper limit	0
Variability estimate	Standard error of the mean
Dispersion value	0.58

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.149
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.55
upper limit	0.35
Variability estimate	Standard error of the mean
Dispersion value	0.57

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.054
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.96
upper limit	0.02
Variability estimate	Standard error of the mean
Dispersion value	0.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3119
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.32
upper limit	0.71
Variability estimate	Standard error of the mean
Dispersion value	0.61

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3947
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.2
upper limit	0.86
Variability estimate	Standard error of the mean
Dispersion value	0.62

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4205
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.18
upper limit	0.93
Variability estimate	Standard error of the mean
Dispersion value	0.64

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0472
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.02
upper limit	-0.02
Variability estimate	Standard error of the mean
Dispersion value	0.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0044
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.55
upper limit	-0.6
Variability estimate	Standard error of the mean
Dispersion value	0.59

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0098
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.4

Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.32
upper limit	-0.41
Variability estimate	Standard error of the mean
Dispersion value	0.58

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1285
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.71
upper limit	0.32
Variability estimate	Standard error of the mean
Dispersion value	0.61

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3243
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.27
upper limit	0.72
Variability estimate	Standard error of the mean
Dispersion value	0.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3795
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.2
upper limit	0.82
Variability estimate	Standard error of the mean
Dispersion value	0.61

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	62
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.307
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.35
upper limit	0.72
Variability estimate	Standard error of the mean
Dispersion value	0.62

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.	

Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1014
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.74
upper limit	0.22
Variability estimate	Standard error of the mean
Dispersion value	0.59

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0033
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.75
upper limit	-0.69
Variability estimate	Standard error of the mean
Dispersion value	0.62

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.028
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-1.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.18
upper limit	-0.17
Variability estimate	Standard error of the mean
Dispersion value	0.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID

Statistical analysis description:

Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.

Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0781
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.98
upper limit	0.15
Variability estimate	Standard error of the mean
Dispersion value	0.64

Secondary: Change From Baseline in PP-NRS Score at Week 14 and 16

End point title	Change From Baseline in PP-NRS Score at Week 14 and 16

End point description:

Subjects were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Wk 14 and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	24	23	20
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Change at Wk 14: n=26,23,23,20,27,24,21,23,18	-0.4 (± 3.18)	-1.4 (± 1.64)	-1.8 (± 3.16)	-1.2 (± 2.52)
Change at Wk 16: n=25,24,22,19,25,27,20,20,16	-0.6 (± 2.97)	-0.9 (± 1.82)	-1.2 (± 3.21)	-0.7 (± 2.02)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	27	21	23
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Change at Wk 14: n=26,23,23,20,27,24,21,23,18	-1.1 (± 2.38)	-1.0 (± 2.93)	-1.1 (± 2.57)	-1.3 (± 2.31)
Change at Wk 16: n=25,24,22,19,25,27,20,20,16	-1.0 (± 2.52)	-0.9 (± 2.99)	-1.0 (± 2.29)	-0.9 (± 2.25)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Change at Wk 14: n=26,23,23,20,27,24,21,23,18	-0.1 (± 4.18)			
Change at Wk 16: n=25,24,22,19,25,27,20,20,16	0.4 (± 3.54)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2

End point title	Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2

End point description:

PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points. '99999' indicates that standard deviation could not be estimated as there was only 1 subject evaluable.

End point type	Secondary

End point timeframe:

Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	36	34	36
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline (n=33, 34, 33, 29, 36, 43, 33, 33, 30)	14.2 (± 5.96)	12.3 (± 7.18)	13.2 (± 6.55)	10.3 (± 5.00)
Week 1 (n=35, 36, 34, 36, 37, 47, 35, 34, 29)	11.2 (± 4.17)	9.1 (± 5.85)	9.7 (± 5.29)	7.8 (± 4.23)
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	10.3 (± 4.57)	8.4 (± 5.07)	9.2 (± 5.03)	7.1 (± 4.01)
Week 4 (n=32, 31, 27, 33, 34, 46, 29, 31, 31)	11.6 (± 5.81)	9.2 (± 5.25)	9.9 (± 5.29)	7.3 (± 3.97)
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	11.6 (± 6.61)	9.7 (± 5.79)	10.4 (± 6.20)	6.2 (± 3.79)
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 28, 27)	11.3 (± 5.82)	8.7 (± 5.87)	9.7 (± 6.62)	6.1 (± 3.73)
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	11.7 (± 7.09)	8.0 (± 6.29)	9.5 (± 5.89)	6.5 (± 3.66)
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	11.7 (± 7.40)	7.8 (± 6.41)	9.7 (± 6.45)	5.9 (± 3.38)
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 23)	14.3 (± 8.09)	8.1 (± 6.37)	8.9 (± 6.09)	6.8 (± 5.00)
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	14.0 (± 7.60)	8.6 (± 6.30)	9.8 (± 5.47)	7.4 (± 5.03)
ET (n=3, 3, 5, 3, 4, 6, 6, 4, 3)	7.7 (± 4.04)	13.0 (± 1.00)	12.8 (± 6.76)	13.3 (± 7.02)
ET follow-up visit 1 (n=2, 1, 2, 1, 1, 2, 2, 1, 1)	7.0 (± 4.24)	9.0 (± 99999)	6.0 (± 4.24)	4.0 (± 99999)
ET follow-up visit 2 (n=2, 1, 2, 1, 2, 4, 2, 4, 2)	8.0 (± 5.66)	7.0 (± 99999)	4.5 (± 2.12)	4.0 (± 99999)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	48	35	35
Units: Unit on a scale				

arithmetic mean (standard deviation)				
Baseline (n=33, 34, 33, 29, 36, 43, 33, 33, 30)	12.3 (± 6.48)	14.0 (± 6.60)	13.0 (± 6.09)	10.1 (± 5.70)
Week 1 (n=35, 36, 34, 36, 37, 47, 35, 34, 29)	8.9 (± 6.10)	9.6 (± 4.86)	9.5 (± 4.86)	7.0 (± 4.96)
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	8.2 (± 5.17)	8.4 (± 4.52)	9.1 (± 5.47)	6.0 (± 4.30)
Week 4 (n=32, 31, 27, 33, 34, 46, 29, 31, 31)	8.1 (± 4.89)	9.6 (± 6.96)	7.9 (± 5.57)	6.6 (± 4.60)
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	7.6 (± 4.69)	8.8 (± 5.96)	6.1 (± 3.23)	6.9 (± 5.06)
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 28, 27)	7.0 (± 4.61)	8.4 (± 5.46)	7.2 (± 4.75)	7.5 (± 4.92)
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	6.4 (± 4.87)	7.8 (± 4.92)	6.7 (± 3.13)	6.7 (± 4.60)
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	6.2 (± 4.69)	8.0 (± 5.13)	6.1 (± 3.67)	6.8 (± 5.14)
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 23)	9.2 (± 6.12)	10.4 (± 5.98)	11.2 (± 7.54)	8.5 (± 6.04)
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	8.9 (± 6.77)	10.4 (± 6.18)	11.5 (± 7.20)	10.2 (± 6.82)
ET (n=3, 3, 5, 3, 4, 6, 6, 4, 3)	15.8 (± 11.73)	18.7 (± 10.23)	18.0 (± 11.87)	11.0 (± 8.21)
ET follow-up visit 1 (n=2, 1, 2, 1, 1, 2, 2, 1, 1)	2.0 (± 99999)	19.0 (± 15.56)	8.5 (± 2.12)	4.0 (± 99999)
ET follow-up visit 2 (n=2, 1, 2, 1, 2, 4, 2, 4, 2)	22.5 (± 9.19)	17.8 (± 11.41)	4.0 (± 0.00)	13.0 (± 13.74)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	31			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline (n=33, 34, 33, 29, 36, 43, 33, 33, 30)	16.6 (± 7.01)			
Week 1 (n=35, 36, 34, 36, 37, 47, 35, 34, 29)	9.7 (± 4.24)			
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	8.4 (± 3.62)			
Week 4 (n=32, 31, 27, 33, 34, 46, 29, 31, 31)	8.3 (± 3.99)			
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	8.2 (± 4.23)			
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 28, 27)	8.0 (± 4.68)			
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	9.5 (± 4.97)			
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	8.3 (± 4.79)			
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 23)	11.5 (± 5.26)			
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	11.9 (± 7.33)			
ET (n=3, 3, 5, 3, 4, 6, 6, 4, 3)	19.3 (± 8.14)			
ET follow-up visit 1 (n=2, 1, 2, 1, 1, 2, 2, 1, 1)	7.0 (± 99999)			

ET follow-up visit 2 (n=2, 1, 2, 1, 2, 4, 2, 4, 2)	15.5 (± 10.61)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2

End point title	Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2

End point description:

PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points. '99999' indicates that standard deviation could not be estimated as there was only 1 subject evaluable.

End point type	Secondary

End point timeframe:

Baseline, Wk 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (ET-FV 1) (2 weeks post ET) and 2 (ET-FV 2) (4 weeks post ET)

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	33	34	32	29
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Change at Wk 1: n=33,34,32,29,36,43,33,33,28	-3.3 (± 4.94)	-2.8 (± 3.35)	-3.0 (± 3.84)	-2.6 (± 2.95)
Change at Wk 2: n=33,33,31,29,34,43,33,33,28	-4.0 (± 5.46)	-3.9 (± 4.91)	-4.1 (± 4.36)	-3.1 (± 3.63)
Change at Wk 4: n=30,28,26,27,33,40,27,29,25	-3.0 (± 6.33)	-3.4 (± 5.09)	-3.5 (± 5.12)	-2.6 (± 3.91)
Change at Wk 6: n=30,28,24,25,28,32,25,26,22	-3.5 (± 7.09)	-3.1 (± 5.30)	-2.0 (± 6.20)	-3.5 (± 5.22)
Change at Wk 8: n=28,28,25,25,26,30,22,27,22	-4.1 (± 7.20)	-3.5 (± 4.60)	-3.2 (± 6.56)	-3.7 (± 5.01)
Change at Wk 10: n=27,25,24,23,28,26,23,27,20	-4.0 (± 7.57)	-4.0 (± 4.90)	-3.4 (± 6.24)	-3.3 (± 6.12)
Change at Wk 12: n=27,26,25,23,27,28,22,27,19	-3.8 (± 7.74)	-4.1 (± 4.98)	-3.2 (± 5.63)	-3.7 (± 6.13)
Change at Wk 14: n=26,23,23,20,27,24,21,24,18	-0.7 (± 7.86)	-2.9 (± 4.68)	-4.4 (± 7.49)	-3.1 (± 6.87)
Change at Wk 16: n=25,24,22,19,25,27,20,21,16	-0.9 (± 7.61)	-2.4 (± 5.02)	-3.2 (± 6.37)	-2.4 (± 7.27)
Change at ET: n=3,3,4,3,4,6,5,3,2	-2.7 (± 2.52)	0.7 (± 6.11)	-1.0 (± 8.29)	0.3 (± 2.08)

Change at ET-FV 1: n=2,1,2,1,1,2,2,1,1	-2.5 (± 0.71)	-9.0 (± 99999)	-5.0 (± 7.07)	-4.0 (± 99999)
Change at ET-FV 2: n=2,1,2,1,2,4,2,4,2	-1.5 (± 2.12)	-11.0 (± 99999)	-6.5 (± 4.95)	-4.0 (± 99999)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	43	33	33
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Change at Wk 1: n=33,34,32,29,36,43,33,33,28	-3.4 (± 4.17)	-3.9 (± 5.00)	-3.7 (± 3.49)	-3.4 (± 3.18)
Change at Wk 2: n=33,33,31,29,34,43,33,33,28	-3.8 (± 4.62)	-5.1 (± 5.85)	-4.2 (± 3.91)	-4.3 (± 4.12)
Change at Wk 4: n=30,28,26,27,33,40,27,29,25	-4.1 (± 4.55)	-3.9 (± 6.50)	-4.6 (± 5.44)	-3.7 (± 4.57)
Change at Wk 6: n=30,28,24,25,28,32,25,26,22	-4.0 (± 4.64)	-5.1 (± 7.40)	-6.3 (± 5.05)	-3.4 (± 4.60)
Change at Wk 8: n=28,28,25,25,26,30,22,27,22	-4.1 (± 5.01)	-5.2 (± 8.12)	-5.8 (± 5.35)	-3.2 (± 4.90)
Change at Wk 10: n=27,25,24,23,28,26,23,27,20	-5.3 (± 5.69)	-5.5 (± 8.08)	-5.1 (± 5.12)	-3.9 (± 4.82)
Change at Wk 12: n=27,26,25,23,27,28,22,27,19	-5.2 (± 6.04)	-5.0 (± 8.15)	-5.2 (± 4.82)	-3.7 (± 5.67)
Change at Wk 14: n=26,23,23,20,27,24,21,24,18	-2.2 (± 5.49)	-3.5 (± 7.87)	-1.4 (± 5.53)	-2.3 (± 4.98)
Change at Wk 16: n=25,24,22,19,25,27,20,21,16	-2.1 (± 6.05)	-2.6 (± 7.12)	-0.8 (± 4.29)	-0.8 (± 5.28)
Change at ET: n=3,3,4,3,4,6,5,3,2	-1.3 (± 6.85)	0.7 (± 5.16)	1.8 (± 7.40)	-4.0 (± 3.00)
Change at ET-FV 1: n=2,1,2,1,1,2,2,1,1	-3.0 (± 99999)	2.0 (± 9.90)	-2.5 (± 0.71)	-7.0 (± 99999)
Change at ET-FV 2: n=2,1,2,1,2,4,2,4,2	6.5 (± 9.19)	0.8 (± 7.14)	-11.0 (± 4.24)	-0.3 (± 8.26)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Change at Wk 1: n=33,34,32,29,36,43,33,33,28	-6.6 (± 4.80)			
Change at Wk 2: n=33,33,31,29,34,43,33,33,28	-7.8 (± 5.37)			
Change at Wk 4: n=30,28,26,27,33,40,27,29,25	-6.5 (± 5.44)			
Change at Wk 6: n=30,28,24,25,28,32,25,26,22	-6.5 (± 5.75)			
Change at Wk 8: n=28,28,25,25,26,30,22,27,22	-7.0 (± 6.64)			
Change at Wk 10: n=27,25,24,23,28,26,23,27,20	-5.8 (± 7.62)			
Change at Wk 12: n=27,26,25,23,27,28,22,27,19	-6.6 (± 7.82)			

Change at Wk 14: n=26,23,23,20,27,24,21,24,18	-2.9 (± 7.98)			
Change at Wk 16: n=25,24,22,19,25,27,20,21,16	-2.7 (± 8.40)			
Change at ET: n=3,3,4,3,4,6,5,3,2	-5.0 (± 1.41)			
Change at ET-FV 1: n=2,1,2,1,1,2,2,1,1	-9.0 (± 99999)			
Change at ET-FV 2: n=2,1,2,1,2,4,2,4,2	-1.0 (± 9.90)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With PGA Score Clear (0) or Almost clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16

End point title	Percentage of Subjects With PGA Score Clear (0) or Almost clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16

End point description:

PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Week 1, 2, 4, 6, 8, 10, 14, and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	37	37	36
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	2.8 (0.3 to 11.6)	2.7 (0.3 to 11.2)	2.7 (0.3 to 11.2)	0 (0.0 to 7.5)
Week 2 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	2.8 (0.3 to 11.6)	0 (0.0 to 7.3)	0 (0.0 to 7.3)	2.8 (0.3 to 11.6)
Week 4 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	5.6 (1.5 to 15.9)	5.4 (1.4 to 15.5)	0 (0.0 to 7.3)	5.6 (1.5 to 15.9)
Week 6 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	8.3 (3.1 to 18.9)	5.4 (1.4 to 15.5)	2.7 (0.3 to 11.2)	8.3 (3.1 to 18.9)
Week 8 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	11.1 (4.9 to 22.9)	5.4 (1.4 to 15.5)	5.4 (1.4 to 15.5)	2.8 (0.3 to 11.6)
Week 10 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	8.3 (3.1 to 18.9)	5.4 (1.4 to 15.5)	8.1 (3.0 to 18.5)	8.3 (3.1 to 18.9)
Week 14 (n=36, 37, 36, 35, 37, 48, 34, 34, 37)	2.8 (0.3 to 11.6)	13.5 (6.7 to 24.8)	5.6 (1.5 to 15.9)	8.6 (3.2 to 19.3)
Week 16 (n=36, 35, 35, 35, 37, 49, 34, 34, 37)	5.6 (1.5 to 15.9)	11.4 (5.1 to 23.6)	8.6 (3.2 to 19.3)	14.3 (7.1 to 26.0)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	35
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	0 (0.0 to 7.3)	0 (0.0 to 5.5)	0 (0.0 to 7.5)	5.7 (1.5 to 16.4)
Week 2 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	2.7 (0.3 to 11.2)	2.0 (0.2 to 8.4)	0 (0.0 to 7.5)	5.7 (1.5 to 16.4)
Week 4 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	5.4 (1.4 to 15.5)	8.2 (3.6 to 16.5)	8.3 (3.1 to 18.9)	11.4 (5.1 to 23.6)
Week 6 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	13.5 (6.7 to 24.8)	8.2 (3.6 to 16.5)	8.3 (3.1 to 18.9)	5.7 (1.5 to 16.4)
Week 8 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	10.8 (4.8 to 22.2)	6.1 (2.3 to 14.8)	13.9 (6.9 to 25.4)	5.7 (1.5 to 16.4)
Week 10 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	16.2 (7.3 to 29.3)	16.3 (8.4 to 27.1)	16.7 (7.5 to 30.2)	8.6 (3.2 to 19.3)
Week 14 (n=36, 37, 36, 35, 37, 48, 34, 34, 37)	13.5 (6.7 to 24.8)	6.3 (2.3 to 15.1)	8.8 (3.3 to 19.7)	11.8 (5.2 to 24.3)
Week 16 (n=36, 35, 35, 35, 37, 49, 34, 34, 37)	16.2 (7.3 to 29.3)	8.2 (3.6 to 16.5)	14.7 (7.3 to 26.9)	11.8 (5.2 to 24.3)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	5.3 (1.4 to 15.0)			
Week 2 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	10.5 (4.7 to 21.6)			
Week 4 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	21.1 (10.9 to 33.3)			
Week 6 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	13.2 (6.5 to 24.3)			
Week 8 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	18.4 (10.1 to 30.9)			
Week 10 (n=36, 37, 37, 36, 37, 49, 36, 35, 38)	13.2 (6.5 to 24.3)			
Week 14 (n=36, 37, 36, 35, 37, 48, 34, 34, 37)	8.1 (3.0 to 18.5)			
Week 16 (n=36, 35, 35, 35, 37, 49, 34, 34, 37)	16.2 (7.3 to 29.3)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4216
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.4
upper limit	9.1

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4216
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.4
upper limit	9.1

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7362
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	5

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7417
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	4.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.9
upper limit	8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0714
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.8
upper limit	16.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0813
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.1
upper limit	15.7

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7417
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	4.7

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.6
upper limit	9.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7417
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	4.7

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4216
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.4
upper limit	9.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6894
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.4
upper limit	5.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0565
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	8.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.3
upper limit	20.3

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2518
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.2
upper limit	14.3

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9001
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-5.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.5
upper limit	1.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4446
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11
upper limit	11

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4446
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11
upper limit	11

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11
upper limit	11

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5054
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.5
upper limit	12.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3401
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.2
upper limit	16.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0489
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	12.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.1
upper limit	27.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8253
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-5.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.2
upper limit	4.4

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6349
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.8
upper limit	8.4

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2709
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.3
upper limit	19.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5054
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.5
upper limit	12.5

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	12.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6319
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.9
upper limit	9.3

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3199
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.4
upper limit	18.1

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7306
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-5.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.1
upper limit	6.1

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7306
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-5.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.1
upper limit	6.1

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8808
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-8.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.6
upper limit	2.7

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4644
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.7
upper limit	13.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1534
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.4
upper limit	20.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4867
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10
upper limit	11.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0435
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	12.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.4
upper limit	25.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6349
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-2.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.8
upper limit	8.4

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4565
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.6
upper limit	12.5

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	12.5

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1765
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.7
upper limit	21.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5013
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14
upper limit	15.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6424
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-3.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.4
upper limit	10.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7969
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-7.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.7
upper limit	5.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.062
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	23.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3402
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7
upper limit	13.4

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1743
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.5
upper limit	17.6

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.062
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	23.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3534
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	2.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.8
upper limit	15.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2508
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.5
upper limit	18.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4238
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	1.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.2
upper limit	13.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2696
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.2
upper limit	19.3

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3648
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.6
upper limit	15.3

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1267
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	8.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.8
upper limit	22.2

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0832
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.5
upper limit	24.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2099
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	6.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.7
upper limit	21.3

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2124
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	8.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4
upper limit	21.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3474
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	3.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8
upper limit	17.4

Secondary: Percentage of Subjects who Achieved PSI Score of 0 (not at all) or 1 (Mild) on all Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

End point title	Percentage of Subjects who Achieved PSI Score of 0 (not at all) or 1 (Mild) on all Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

End point description:

PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity. EAS included all randomised subjects who received at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	36	34	36
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=35, 36, 34, 36, 37, 47, 35, 34, 29)	5.7 (1.5 to 16.4)	19.4 (10.7 to 32.8)	11.8 (5.2 to 24.3)	22.2 (11.6 to 35.3)
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	8.6 (3.2 to 19.3)	22.2 (11.6 to 35.3)	18.2 (8.2 to 31.3)	34.3 (22.0 to 47.8)
Week 4 (n=32, 31, 27, 33, 34, 46, 29, 31, 31)	15.6 (7.8 to 28.7)	29.0 (17.6 to 45.0)	29.6 (15.7 to 45.3)	48.5 (34.4 to 63.9)
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	18.8 (8.5 to 32.0)	26.7 (14.0 to 41.6)	32.0 (17.0 to 50.0)	54.8 (39.9 to 70.3)
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 28, 27)	23.3 (12.9 to 37.6)	35.5 (21.3 to 51.8)	46.2 (29.9 to 63.8)	67.7 (51.8 to 81.3)
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	31.0 (18.9 to 46.3)	42.9 (28.4 to 60.0)	40.0 (24.6 to 58.3)	62.1 (46.3 to 77.1)
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	24.1 (13.4 to 38.5)	51.7 (35.2 to 68.0)	50.0 (34.2 to 65.8)	62.1 (46.3 to 77.1)

Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 23)	7.1 (1.9 to 20.1)	44.0 (27.0 to 61.1)	45.8 (28.2 to 63.0)	54.2 (37.0 to 71.8)
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	7.4 (2.0 to 20.4)	44.4 (29.1 to 61.8)	30.4 (17.3 to 47.9)	54.2 (37.0 to 71.8)

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	48	35	35
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=35, 36, 34, 36, 37, 47, 35, 34, 29)	13.5 (6.7 to 24.8)	19.1 (11.2 to 30.3)	11.4 (5.1 to 23.6)	26.5 (15.9 to 40.5)
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	31.4 (19.3 to 44.8)	20.8 (11.8 to 31.5)	25.7 (15.4 to 39.2)	31.4 (19.3 to 44.8)
Week 4 (n=32, 31, 27, 33, 34, 46, 29, 31, 31)	38.2 (24.3 to 53.8)	26.1 (15.8 to 37.7)	31.0 (18.9 to 46.3)	51.6 (36.8 to 67.3)
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	42.9 (28.4 to 60.0)	31.6 (19.9 to 45.9)	66.7 (50.0 to 79.6)	48.1 (32.6 to 65.3)
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 28, 27)	50.0 (34.2 to 65.8)	41.7 (29.0 to 56.0)	62.5 (44.7 to 77.9)	35.7 (20.8 to 52.7)
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	64.3 (47.3 to 79.2)	45.2 (29.7 to 60.1)	50.0 (31.9 to 68.1)	46.4 (31.0 to 63.4)
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	55.6 (38.2 to 70.9)	35.5 (21.3 to 51.8)	56.5 (38.1 to 72.7)	46.4 (31.0 to 63.4)
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 23)	37.0 (22.1 to 54.7)	25.9 (14.5 to 41.7)	30.4 (17.3 to 47.9)	36.0 (21.4 to 54.4)
Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	52.0 (36.0 to 69.3)	36.7 (22.1 to 52.4)	18.2 (8.2 to 35.3)	22.7 (11.5 to 39.5)

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	31			
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 1 (n=35, 36, 34, 36, 37, 47, 35, 34, 29)	24.1 (13.4 to 38.5)			
Week 2 (n=35, 36, 33, 35, 35, 48, 35, 35, 31)	32.3 (18.7 to 48.2)			
Week 4 (n=32, 31, 27, 33, 34, 46, 29, 31, 31)	35.5 (21.3 to 51.8)			
Week 6 (n=32, 30, 25, 31, 28, 38, 27, 27, 27)	33.3 (20.4 to 50.0)			
Week 8 (n=30, 31, 26, 31, 26, 36, 24, 28, 27)	59.3 (41.7 to 75.2)			
Week 10 (n=29, 28, 25, 29, 28, 31, 24, 28, 24)	33.3 (17.8 to 52.1)			
Week 12 (n=29, 29, 26, 29, 27, 31, 23, 28, 25)	36.0 (21.4 to 54.4)			
Week 14 (n=28, 25, 24, 24, 27, 27, 23, 25, 23)	17.4 (7.8 to 33.5)			

Week 16 (n=27, 27, 23, 24, 25, 30, 22, 22, 19)	31.6 (15.1 to 53.0)			

Statistical analyses

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2697
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	6.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.3
upper limit	19.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0544
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	13.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.3
upper limit	27.9

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0286
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	16.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	2
upper limit	31

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 1	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1512
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.7
upper limit	20.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3137
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.5
upper limit	24

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.79
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-7.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21.9
upper limit	7.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 1	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3789
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.9
upper limit	22.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0636
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	13.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1
upper limit	28.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1435
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	9.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.9
upper limit	24.5

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0058
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	25.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.9
upper limit	42.4

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 2	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0112
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	22.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.5
upper limit	38.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3349
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.8
upper limit	21.3

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2065
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.1
upper limit	27.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 2	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1871
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	11.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.6
upper limit	29.1

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1245
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	13.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.9
upper limit	31.4

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.128
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	14
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.7
upper limit	33.7

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0235
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	22.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.1
upper limit	40.6

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 4	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	32.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	12.4
upper limit	50.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3728
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.6
upper limit	24.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0153
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	25.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	4
upper limit	43.6

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2785
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	7.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.2
upper limit	26.4

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 4	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2543
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	9.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.8
upper limit	27.8

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1434
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	13.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.4
upper limit	33.7

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0015
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	36.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	12.8
upper limit	54.1

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 6	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0242
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	24.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.4
upper limit	43.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0037
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	35.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	10
upper limit	54.1

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1037
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	16.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.9
upper limit	36.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 6	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4607
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	1.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.7
upper limit	22.5

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1725
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	12.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-8
upper limit	31.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0451
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	22.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.2
upper limit	43.6

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	44.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	21.3
upper limit	62.9

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 8	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0239
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	26.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.8
upper limit	47.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID

Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0643
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	20.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.1
upper limit	41.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6676
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.9
upper limit	15.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 8	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0898
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	17.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.2
upper limit	37.8

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2707
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	11.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.1
upper limit	32.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2981
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.2
upper limit	31

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.011
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	31
Confidence interval	
level	90 %
sides	2-sided
lower limit	8
upper limit	51.4

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 10	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0083
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	33.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	9.1
upper limit	53.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4217
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-18.3
upper limit	27.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5152
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	1.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.8
upper limit	23.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 10	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7002
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-11.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-33.1
upper limit	11.7

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD

Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0169
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	27.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.2
upper limit	47.9

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description:	
Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0283
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	25.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.2
upper limit	46.2

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	37.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	14.3
upper limit	57.1

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 12	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0095
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	31.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.4
upper limit	51.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 12	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0798
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	21
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.7
upper limit	42.6

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 12	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID

Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2848
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.3
upper limit	31.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description:	
Week 12	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5062
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21.1
upper limit	23.1

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description:	
Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0012
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	36.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	16.7
upper limit	55.3

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	38.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	17.3
upper limit	57.4

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	47
Confidence interval	
level	90 %
sides	2-sided
lower limit	24.6
upper limit	65.1

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description: Week 14	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD

Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0039
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	29.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	9.5
upper limit	48.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description:	
Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3895
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	4.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.5
upper limit	26.5

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description:	
Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2793
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	10.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.8
upper limit	31.8

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 14	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7027
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-8.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-28.4
upper limit	12.2

Statistical analysis title	Vehicle QD versus PF-06700841 0.1% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.1% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0009
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	37
Confidence interval	
level	90 %
sides	2-sided
lower limit	15.4
upper limit	55.2

Statistical analysis title	Vehicle QD versus PF-06700841 0.3% QD
Statistical analysis description: Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 0.3% QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0205
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	23
Confidence interval	
level	90 %
sides	2-sided
lower limit	4.1
upper limit	43.2

Statistical analysis title	Vehicle QD versus PF-06700841 1.0% QD
Statistical analysis description:	
Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 1.0% QD
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	46.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	24.6
upper limit	65.7

Statistical analysis title	Vehicle QD versus PF-06700841 3.0% QD
Statistical analysis description:	
Week 16	
Comparison groups	Vehicle Once Daily (QD) v PF-06700841 3.0% QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	44.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	21.5
upper limit	62.9

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 0.3% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 0.3% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9209
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-18.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-38.3
upper limit	3.2

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 1.0% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 1.0% BID
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.793
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-13.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.4
upper limit	8.7

Statistical analysis title	Pooled Vehicle BID versus PF-06700841 3.0% BID
Statistical analysis description: Week 16	
Comparison groups	Pooled Vehicle Twice Daily (BID) v PF-06700841 3.0% BID

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6156
Method	Chan and Zhang method
Parameter estimate	Risk difference (RD)
Point estimate	-5.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-28
upper limit	20.1

Secondary: Number of Subjects With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs

End point title	Number of Subjects With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a subject who received study drug. Relatedness to study drug was assessed by the investigator. Safety analysis set (SAS) included subjects who received at least 1 dose of investigational product.

End point type	Secondary

End point timeframe:

Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	37	36
Units: Subjects				
Treatment-emergent AEs	17	16	14	17
Treatment-emergent SAEs	1	0	0	1
Treatment-related AEs	1	0	2	2
Treatment-related SAEs	0	0	0	0

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	36

Units: Subjects				
Treatment-emergent AEs	14	20	13	18
Treatment-emergent SAEs	0	1	1	2
Treatment-related AEs	3	2	3	3
Treatment-related SAEs	0	0	0	0

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects				
Treatment-emergent AEs	12			
Treatment-emergent SAEs	0			
Treatment-related AEs	1			
Treatment-related SAEs	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With TEAEs by Severity

End point title	Number of Subjects With TEAEs by Severity

End point description:

An AE was any untoward medical occurrence in a subjects who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to AE) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to AE). SAS included subjects who received at least 1 dose of investigational product.

End point type	Secondary

End point timeframe:

Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	37	36
Units: Subjects				
Mild	12	9	11	11
Moderate	5	7	3	5
Severe	0	0	0	1

End point values	PF-06700841	Pooled Vehicle	PF-06700841	PF-06700841

	3.0% QD	Twice Daily (BID)	0.3% BID	1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	36
Units: Subjects				
Mild	7	8	7	11
Moderate	7	11	6	5
Severe	0	1	0	2

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects				
Mild	6			
Moderate	6			
Severe	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects who Discontinued From Study due to Adverse Events

End point title	Number of Subjects who Discontinued From Study due to Adverse Events

End point description:

An AE was any untoward medical occurrence in a subjects who received investigational product without regard to possibility of causal relationship. SAS included subjects who received at least 1 dose of investigational product.

End point type	Secondary

End point timeframe:

Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	37	36
Units: Subjects	1	1	3	0

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	36
Units: Subjects	2	1	1	2

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Laboratory Abnormalities Meeting Specified Criteria

End point title	Number of Subjects With Laboratory Abnormalities Meeting Specified Criteria

End point description:

Bilirubin: greater than (>) 1.5* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: >2.5*ULN; creatinine, cystatin C: >1.3*ULN; creatine kinase: >2.0*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (<) 60 milliliter (mL)/minute (min)/1.73 meter(m)^2, greater than or equal to (>=) 30% decrease from baseline; GFR: <60 mL/min/1.73m^2. SAS included subjects who received at least 1 dose of investigational product. Here, number of subjects analysed=subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	36	36	36
Units: Subjects	7	6	11	7

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	36
Units: Subjects	5	12	5	6

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects	15			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data

End point title	Number of Subjects With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data

End point description:

Following were ECG criteria used for categorical summary:1) PR interval: percentage change >=25/50%, QRS interval: value >140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec < value less than equal to (<=) 480 and 30 < change <=60. SAS included subjects who received at least 1 dose of investigational product.

End point type	Secondary

End point timeframe:

Post-baseline to Wk 6, Post-baseline to Wk 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	37	36
Units: Subjects				
Post-baseline to Wk 6:PR interval >=25/50%	0	0	0	1
Post-baseline to Wk 6:QRS interval >=140 msec	0	1	0	0
Post-baseline to Wk 6:QTcF interval 30<Change<=60	1	0	0	1
Post-baseline to Wk 12:PR interval >=25/50%	0	0	0	1
Post-baseline to Wk 12:QRS interval >=140 msec	0	1	0	0
Post-baseline to Wk12:QTcF interval 450<Value<=480	0	0	0	0
Post-baseline to Wk 12:QTcF interval 30<Change<=60	2	0	0	0

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	36
Units: Subjects				

Post-baseline to Wk 6:PR interval >=25/50%	0	1	0	0
Post-baseline to Wk 6:QRS interval >=140 msec	0	1	0	0
Post-baseline to Wk 6:QTcF interval 30<Change<=60	1	0	0	0
Post-baseline to Wk 12:PR interval >=25/50%	1	1	0	0
Post-baseline to Wk 12:QRS interval >=140 msec	0	2	0	1
Post-baseline to Wk12:QTcF interval 450<Value<=480	0	2	1	1
Post-baseline to Wk 12:QTcF interval 30<Change<=60	0	2	0	0

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects				
Post-baseline to Wk 6:PR interval >=25/50%	0			
Post-baseline to Wk 6:QRS interval >=140 msec	0			
Post-baseline to Wk 6:QTcF interval 30<Change<=60	2			
Post-baseline to Wk 12:PR interval >=25/50%	0			
Post-baseline to Wk 12:QRS interval >=140 msec	0			
Post-baseline to Wk12:QTcF interval 450<Value<=480	1			
Post-baseline to Wk 12:QTcF interval 30<Change<=60	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Categorical Summary of Post-Baseline Vital Signs Data

End point title	Number of Subjects With Categorical Summary of Post-Baseline Vital Signs Data

End point description:

Following were the vital signs criteria: 1) Pulse rate: value <40 beats per min (bpm), value >120 bpm; 2) Sitting (Sit.) diastolic blood pressure (DBP): value <50 mmHg; change >=20 mmHg increase (inc.); change >=20 mmHg decrease (dec.); 3) Sit. systolic blood pressure (SBP): value <90 mmHg, change >=30 mmHg inc., change >=30 mmHg dec.; 4) Supine (Sup.) DBP: value <50 mmHg, change >=20 mmHg inc., change >=20 mmHg dec.; 5) Sup. SBP: value <90 mmHg, change >=30 mmHg inc., change >=30 mmHg dec.. SAS included subjects who received at least 1 dose of investigational product. Here, number of subjects analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:
Post-baseline to Week 12

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	34	33	33
Units: Subjects				
Pulse rate <40 bpm: n=35,34,33,33,34,47,32,36,34	0	0	0	0
Pulse rate >120 bpm: n=35,34,33,33,34,47,32,36,34	0	0	0	0
Sit. DBP <50mmHg: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. DBP >=20mmHg inc.: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. DBP >=20mmHg dec.: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. SBP <90mmHg: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. SBP >= 30mmHg inc.: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. SBP >=30mmHg dec.: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sup.DBP <50mmHg:n=32,25,29,29,28,42,25,31,	0	0	0	0
Sup.DBP>= 20mmHg inc.:n=32,25,29,29,28,42,25,31,31	0	1	1	1
Sup.DBP>=20mmHg dec.:n=32,25,29,29,28,42,25,31,31	0	2	0	0
Sup.SBP <90mmHg:n=32,25,29,29,28,42,25,31,	1	0	0	0
Sup.SBP>=30mmHg inc.:n=32,25,29,29,28,42,25,31,31	1	0	1	2
Sup.SBP>= 30mmHg dec.:n=32,25,29,29,28,42,25,31,31	1	0	1	1

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	47	32	36
Units: Subjects				
Pulse rate <40 bpm: n=35,34,33,33,34,47,32,36,34	0	0	0	0
Pulse rate >120 bpm: n=35,34,33,33,34,47,32,36,34	0	0	0	0
Sit. DBP <50mmHg: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. DBP >=20mmHg inc.: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. DBP >=20mmHg dec.: n=3,11,5,5,6,5,8,6,5	0	0	0	0

Sit. SBP <90mmHg: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. SBP >= 30mmHg inc.: n=3,11,5,5,6,5,8,6,5	0	0	0	0
Sit. SBP >=30mmHg dec.: n=3,11,5,5,6,5,8,6,5	0	0	0	1
Sup.DBP <50mmHg:n=32,25,29,29,28,42,25,31,	0	0	0	0
Sup.DBP>= 20mmHg inc.:n=32,25,29,29,28,42,25,31,31	0	0	0	2
Sup.DBP>=20mmHg dec.:n=32,25,29,29,28,42,25,31,31	1	4	0	0
Sup.SBP <90mmHg:n=32,25,29,29,28,42,25,31,	0	0	0	0
Sup.SBP>=30mmHg inc.:n=32,25,29,29,28,42,25,31,31	0	2	0	2
Sup.SBP>= 30mmHg dec.:n=32,25,29,29,28,42,25,31,31	0	0	1	1

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	34			
Units: Subjects				
Pulse rate <40 bpm: n=35,34,33,33,34,47,32,36,34	0			
Pulse rate >120 bpm: n=35,34,33,33,34,47,32,36,34	0			
Sit. DBP <50mmHg: n=3,11,5,5,6,5,8,6,5	0			
Sit. DBP >=20mmHg inc.: n=3,11,5,5,6,5,8,6,5	0			
Sit. DBP >=20mmHg dec.: n=3,11,5,5,6,5,8,6,5	0			
Sit. SBP <90mmHg: n=3,11,5,5,6,5,8,6,5	0			
Sit. SBP >= 30mmHg inc.: n=3,11,5,5,6,5,8,6,5	1			
Sit. SBP >=30mmHg dec.: n=3,11,5,5,6,5,8,6,5	0			
Sup.DBP <50mmHg:n=32,25,29,29,28,42,25,31,	0			
Sup.DBP>= 20mmHg inc.:n=32,25,29,29,28,42,25,31,31	2			
Sup.DBP>=20mmHg dec.:n=32,25,29,29,28,42,25,31,31	0			
Sup.SBP <90mmHg:n=32,25,29,29,28,42,25,31,	0			
Sup.SBP>=30mmHg inc.:n=32,25,29,29,28,42,25,31,31	1			
Sup.SBP>= 30mmHg dec.:n=32,25,29,29,28,42,25,31,31	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Classified per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16

End point title	Number of Subjects Classified per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16

End point description:

At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent [if still in place]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent [if still in place]). SAS included subjects who received at least 1 dose of investigational product. Here, n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16

End point values	Vehicle Once Daily (QD)	PF-06700841 0.1% QD	PF-06700841 0.3% QD	PF-06700841 1.0% QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	37	36
Units: Subjects				
Day 1: None (n=37,37,37,36,37,49,36,36,38)	36	37	36	36
Day 1: Mild (n=37,37,37,36,37,49,36,36,38)	1	0	1	0
Day 1: Moderate (n=37,37,37,36,37,49,36,36,38)	0	0	0	0
Day 1: Severe (n=37,37,37,36,37,49,36,36,38)	0	0	0	0
Day 1:Very severe (n=37,37,37,36,37,49,36,36,38)	0	0	0	0
Day 1: Missing (n=37,37,37,36,37,49,36,36,38)	0	0	0	0
Week 1: None (n=36,36,37,36,37,49,36,36,37)	32	35	32	34
Week 1: Mild (n=36,36,37,36,37,49,36,36,37)	1	0	1	2
Week 1: Moderate (n=36,36,37,36,37,49,36,36,37)	0	0	0	0
Week 1: Severe (n=36,36,37,36,37,49,36,36,37)	0	0	0	0
Week 1:Very severe (n=36,36,37,36,37,49,36,36,37)	0	0	0	0
Week 1: Missing (n=36,36,37,36,37,49,36,36,37)	3	1	4	0
Week 2: None (n=35,36,36,36,36,48,35,36,37)	33	35	30	34
Week 2: Mild (n=35,36,36,36,36,48,35,36,37)	1	0	1	1
Week 2: Moderate (n=35,36,36,36,36,48,35,36,37)	0	0	0	0
Week 2: Severe (n=35,36,36,36,36,48,35,36,37)	0	0	0	0

Week 2:Very severe (n=35,36,36,36,36,48,35,36,37)	0	0	0	0
Week 2: Missing (n=35,36,36,36,36,48,35,36,37)	1	1	5	1
Week 4: None (n=34,34,34,35,35,47,32,35,35)	34	32	29	32
Week 4: Mild (n=34,34,34,35,35,47,32,35,35)	0	0	0	2
Week 4: Moderate (n=34,34,34,35,35,47,32,35,35)	0	0	0	0
Week 4: Severe (n=34,34,34,35,35,47,32,35,35)	0	0	0	0
Week 4:Very severe (n=34,34,34,35,35,47,32,35,35)	0	0	0	0
Week 4: Missing (n=34,34,34,35,35,47,32,35,35)	0	2	5	1
Week 6: None (n=33,32,32,35,31,44,31,35,32)	32	31	26	30
Week 6: Mild (n=33,32,32,35,31,44,31,35,32)	0	0	1	1
Week 6: Moderate (n=33,32,32,35,31,44,31,35,32)	0	0	0	0
Week 6: Severe (n=33,32,32,35,31,44,31,35,32)	0	0	0	0
Week 6:Very severe (n=33,32,32,35,31,44,31,35,32)	0	0	0	0
Week 6: Missing (n=33,32,32,35,31,44,31,35,32)	1	1	5	4
Week 8: None (n=32,32,33,35,31,41,29,34,32)	29	30	27	30
Week 8: Mild (n=32,32,33,35,31,41,29,34,32)	0	0	0	0
Week 8: Moderate (n=32,32,33,35,31,41,29,34,32)	1	0	0	1
Week 8: Severe (n=32,32,33,35,31,41,29,34,32)	0	0	0	0
Week 8:Very severe (n=32,32,33,35,31,41,29,34,32)	0	0	0	0
Week 8: Missing (n=32,32,33,35,31,41,29,34,32)	2	2	6	4
Week 10: None (n=32,31,32,33,31,40,28,34,30)	29	30	24	29
Week 10: Mild (n=32,31,32,33,31,40,28,34,30)	0	0	1	1
Week 10: Moderate (n=32,31,32,33,31,40,28,34,30)	0	0	0	0
Week 10: Severe (n=32,31,32,33,31,40,28,34,30)	0	0	0	0
Week 10:Very severe (n=32,31,32,33,31,40,28,34,30)	0	0	0	0
Week 10: Missing (n=32,31,32,33,31,40,28,34,30)	3	1	7	3
Week 12: None (n=36,36,36,35,35,46,34,36,35)	33	32	30	31
Week 12: Mild (n=36,36,36,35,35,46,34,36,35)	0	0	0	1
Week 12: Moderate (n=36,36,36,35,35,46,34,36,35)	0	0	0	0
Week 12: Severe (n=36,36,36,35,35,46,34,36,35)	0	0	0	0
Week 12:Very severe (n=36,36,36,35,35,46,34,36,35)	0	0	0	0

Week 12: Missing (n=36,36,36,35,35,46,34,36,35)	3	4	6	3
Week 14: None (n=36,34,34,34,34,45,34,35,33)	31	27	24	27
Week 14: Mild (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14: Moderate (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14: Severe (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14:Very severe (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14: Missing (n=36,34,34,34,34,45,34,35,33)	5	7	10	5
Week 16: None (n=35,35,35,35,32,45,34,35,33)	31	28	26	28
Week 16: Mild (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16: Moderate (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16: Severe (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16:Very severe (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16: Missing (n=35,35,35,35,32,45,34,35,33)	4	7	9	7

End point values	PF-06700841 3.0% QD	Pooled Vehicle Twice Daily (BID)	PF-06700841 0.3% BID	PF-06700841 1.0% BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	49	36	36
Units: Subjects				
Day 1: None (n=37,37,37,36,37,49,36,36,38)	36	48	35	36
Day 1: Mild (n=37,37,37,36,37,49,36,36,38)	1	0	0	0
Day 1: Moderate (n=37,37,37,36,37,49,36,36,38)	0	0	1	0
Day 1: Severe (n=37,37,37,36,37,49,36,36,38)	0	0	0	0
Day 1:Very severe (n=37,37,37,36,37,49,36,36,38)	0	0	0	0
Day 1: Missing (n=37,37,37,36,37,49,36,36,38)	0	1	0	0
Week 1: None (n=36,36,37,36,37,49,36,36,37)	35	44	32	32
Week 1: Mild (n=36,36,37,36,37,49,36,36,37)	0	1	0	2
Week 1: Moderate (n=36,36,37,36,37,49,36,36,37)	0	0	0	0
Week 1: Severe (n=36,36,37,36,37,49,36,36,37)	0	0	0	0
Week 1:Very severe (n=36,36,37,36,37,49,36,36,37)	0	0	0	0
Week 1: Missing (n=36,36,37,36,37,49,36,36,37)	2	4	4	2

Week 2: None (n=35,36,36,36,36,48,35,36,37)	35	45	34	35
Week 2: Mild (n=35,36,36,36,36,48,35,36,37)	0	1	0	0
Week 2: Moderate (n=35,36,36,36,36,48,35,36,37)	0	0	1	0
Week 2: Severe (n=35,36,36,36,36,48,35,36,37)	0	0	0	0
Week 2:Very severe (n=35,36,36,36,36,48,35,36,37)	0	0	0	0
Week 2: Missing (n=35,36,36,36,36,48,35,36,37)	1	2	0	1
Week 4: None (n=34,34,34,35,35,47,32,35,35)	34	44	30	32
Week 4: Mild (n=34,34,34,35,35,47,32,35,35)	0	1	0	0
Week 4: Moderate (n=34,34,34,35,35,47,32,35,35)	0	0	0	0
Week 4: Severe (n=34,34,34,35,35,47,32,35,35)	0	0	0	0
Week 4:Very severe (n=34,34,34,35,35,47,32,35,35)	0	0	0	0
Week 4: Missing (n=34,34,34,35,35,47,32,35,35)	1	2	2	3
Week 6: None (n=33,32,32,35,31,44,31,35,32)	27	37	28	31
Week 6: Mild (n=33,32,32,35,31,44,31,35,32)	1	0	0	0
Week 6: Moderate (n=33,32,32,35,31,44,31,35,32)	0	0	0	0
Week 6: Severe (n=33,32,32,35,31,44,31,35,32)	0	0	0	0
Week 6:Very severe (n=33,32,32,35,31,44,31,35,32)	0	0	0	0
Week 6: Missing (n=33,32,32,35,31,44,31,35,32)	3	7	3	4
Week 8: None (n=32,32,33,35,31,41,29,34,32)	26	34	26	30
Week 8: Mild (n=32,32,33,35,31,41,29,34,32)	1	1	0	0
Week 8: Moderate (n=32,32,33,35,31,41,29,34,32)	0	0	0	0
Week 8: Severe (n=32,32,33,35,31,41,29,34,32)	0	0	0	0
Week 8:Very severe (n=32,32,33,35,31,41,29,34,32)	0	0	0	0
Week 8: Missing (n=32,32,33,35,31,41,29,34,32)	4	6	3	4
Week 10: None (n=32,31,32,33,31,40,28,34,30)	27	34	24	27
Week 10: Mild (n=32,31,32,33,31,40,28,34,30)	1	0	0	0
Week 10: Moderate (n=32,31,32,33,31,40,28,34,30)	0	0	0	0
Week 10: Severe (n=32,31,32,33,31,40,28,34,30)	0	0	0	0
Week 10:Very severe (n=32,31,32,33,31,40,28,34,30)	0	0	0	0
Week 10: Missing (n=32,31,32,33,31,40,28,34,30)	3	6	4	7
Week 12: None (n=36,36,36,35,35,46,34,36,35)	30	43	30	32

Week 12: Mild (n=36,36,36,35,35,46,34,36,35)	1	0	0	0
Week 12: Moderate (n=36,36,36,35,35,46,34,36,35)	0	0	1	1
Week 12: Severe (n=36,36,36,35,35,46,34,36,35)	0	0	0	0
Week 12:Very severe (n=36,36,36,35,35,46,34,36,35)	0	0	0	0
Week 12: Missing (n=36,36,36,35,35,46,34,36,35)	4	3	3	3
Week 14: None (n=36,34,34,34,34,45,34,35,33)	30	34	26	26
Week 14: Mild (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14: Moderate (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14: Severe (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14:Very severe (n=36,34,34,34,34,45,34,35,33)	0	0	0	0
Week 14: Missing (n=36,34,34,34,34,45,34,35,33)	4	11	8	9
Week 16: None (n=35,35,35,35,32,45,34,35,33)	28	35	26	28
Week 16: Mild (n=35,35,35,35,32,45,34,35,33)	0	0	0	1
Week 16: Moderate (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16: Severe (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16:Very severe (n=35,35,35,35,32,45,34,35,33)	0	0	0	0
Week 16: Missing (n=35,35,35,35,32,45,34,35,33)	4	10	8	6

End point values	PF-06700841 3.0% BID			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects				
Day 1: None (n=37,37,37,36,37,49,36,36,38)	37			
Day 1: Mild (n=37,37,37,36,37,49,36,36,38)	1			
Day 1: Moderate (n=37,37,37,36,37,49,36,36,38)	0			
Day 1: Severe (n=37,37,37,36,37,49,36,36,38)	0			
Day 1:Very severe (n=37,37,37,36,37,49,36,36,38)	0			
Day 1: Missing (n=37,37,37,36,37,49,36,36,38)	0			
Week 1: None (n=36,36,37,36,37,49,36,36,37)	35			
Week 1: Mild (n=36,36,37,36,37,49,36,36,37)	1			
Week 1: Moderate (n=36,36,37,36,37,49,36,36,37)	0			

Week 1: Severe (n=36,36,37,36,37,49,36,36,37)	0			
Week 1:Very severe (n=36,36,37,36,37,49,36,36,37)	0			
Week 1: Missing (n=36,36,37,36,37,49,36,36,37)	1			
Week 2: None (n=35,36,36,36,36,48,35,36,37)	33			
Week 2: Mild (n=35,36,36,36,36,48,35,36,37)	2			
Week 2: Moderate (n=35,36,36,36,36,48,35,36,37)	0			
Week 2: Severe (n=35,36,36,36,36,48,35,36,37)	0			
Week 2:Very severe (n=35,36,36,36,36,48,35,36,37)	0			
Week 2: Missing (n=35,36,36,36,36,48,35,36,37)	2			
Week 4: None (n=34,34,34,35,35,47,32,35,35)	30			
Week 4: Mild (n=34,34,34,35,35,47,32,35,35)	3			
Week 4: Moderate (n=34,34,34,35,35,47,32,35,35)	0			
Week 4: Severe (n=34,34,34,35,35,47,32,35,35)	0			
Week 4:Very severe (n=34,34,34,35,35,47,32,35,35)	0			
Week 4: Missing (n=34,34,34,35,35,47,32,35,35)	2			
Week 6: None (n=33,32,32,35,31,44,31,35,32)	30			
Week 6: Mild (n=33,32,32,35,31,44,31,35,32)	0			
Week 6: Moderate (n=33,32,32,35,31,44,31,35,32)	0			
Week 6: Severe (n=33,32,32,35,31,44,31,35,32)	0			
Week 6:Very severe (n=33,32,32,35,31,44,31,35,32)	0			
Week 6: Missing (n=33,32,32,35,31,44,31,35,32)	2			
Week 8: None (n=32,32,33,35,31,41,29,34,32)	28			
Week 8: Mild (n=32,32,33,35,31,41,29,34,32)	0			
Week 8: Moderate (n=32,32,33,35,31,41,29,34,32)	0			
Week 8: Severe (n=32,32,33,35,31,41,29,34,32)	0			
Week 8:Very severe (n=32,32,33,35,31,41,29,34,32)	0			
Week 8: Missing (n=32,32,33,35,31,41,29,34,32)	4			
Week 10: None (n=32,31,32,33,31,40,28,34,30)	26			
Week 10: Mild (n=32,31,32,33,31,40,28,34,30)	0			
Week 10: Moderate (n=32,31,32,33,31,40,28,34,30)	0			
Week 10: Severe (n=32,31,32,33,31,40,28,34,30)	0			

Week 10:Very severe (n=32,31,32,33,31,40,28,34,30)	0			
Week 10: Missing (n=32,31,32,33,31,40,28,34,30)	4			
Week 12: None (n=36,36,36,35,35,46,34,36,35)	29			
Week 12: Mild (n=36,36,36,35,35,46,34,36,35)	0			
Week 12: Moderate (n=36,36,36,35,35,46,34,36,35)	1			
Week 12: Severe (n=36,36,36,35,35,46,34,36,35)	0			
Week 12:Very severe (n=36,36,36,35,35,46,34,36,35)	0			
Week 12: Missing (n=36,36,36,35,35,46,34,36,35)	5			
Week 14: None (n=36,34,34,34,34,45,34,35,33)	28			
Week 14: Mild (n=36,34,34,34,34,45,34,35,33)	0			
Week 14: Moderate (n=36,34,34,34,34,45,34,35,33)	0			
Week 14: Severe (n=36,34,34,34,34,45,34,35,33)	0			
Week 14:Very severe (n=36,34,34,34,34,45,34,35,33)	0			
Week 14: Missing (n=36,34,34,34,34,45,34,35,33)	5			
Week 16: None (n=35,35,35,35,32,45,34,35,33)	26			
Week 16: Mild (n=35,35,35,35,32,45,34,35,33)	0			
Week 16: Moderate (n=35,35,35,35,32,45,34,35,33)	0			
Week 16: Severe (n=35,35,35,35,32,45,34,35,33)	0			
Week 16:Very severe (n=35,35,35,35,32,45,34,35,33)	0			
Week 16: Missing (n=35,35,35,35,32,45,34,35,33)	7			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

Adverse event reporting additional description:

Same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be classified as serious in 1 subject and as non-serious in another subject, or 1 subject may have experienced both a SAE and non-SAE during the study. SAS included subjects who received at least 1 dose of investigational product.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	24.0

Reporting groups

Reporting group title	PF-06700841 0.1% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Vehicle Once Daily (QD)

Reporting group description:

During stage 1 of the study subjects topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 1% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 3.0% QD

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Pooled Vehicle BID

Reporting group description:

During stage 1 and 2 of the study subjects topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% BID

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% BID

Reporting group description:

During stage 1 of the study subjects topically applied PF-06700841 1% cream on psoriatic areas BID for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 3.0% BID

Reporting group description:

During stage 2 of the study subjects topically applied PF-06700841 3% cream on psoriatic areas QD for a maximum of 12 weeks. Subjects were followed up for 4 weeks after last dose.

Serious adverse events	PF-06700841 0.1% QD	Vehicle Once Daily (QD)	PF-06700841 1.0% QD
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	1 / 36 (2.78%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Investigations			
Aspiration bursa			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiopulmonary failure			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Lethargy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			

subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis septic			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-06700841 0.3% QD	PF-06700841 3.0% QD	Pooled Vehicle BID
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 49 (2.04%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Investigations			
Aspiration bursa			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiopulmonary failure			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
Lethargy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			

subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis septic			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-06700841 0.3% BID	PF-06700841 1.0% BID	PF-06700841 3.0% BID
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 36 (2.78%)	2 / 36 (5.56%)	0 / 38 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Investigations			
Aspiration bursa			
subjects affected / exposed	0 / 36 (0.00%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiopulmonary failure			

subjects affected / exposed	0 / 36 (0.00%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Lethargy			
subjects affected / exposed	0 / 36 (0.00%)	1 / 36 (2.78%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 36 (0.00%)	1 / 36 (2.78%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 36 (2.78%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 36 (0.00%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis septic			
subjects affected / exposed	0 / 36 (0.00%)	1 / 36 (2.78%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 36 (0.00%)	1 / 36 (2.78%)	0 / 38 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PF-06700841 0.1% QD	Vehicle Once Daily (QD)	PF-06700841 1.0% QD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 37 (18.92%)	7 / 37 (18.92%)	9 / 36 (25.00%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	2 / 36 (5.56%)
occurrences (all)	0	1	2
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 37 (5.41%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	3	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	1 / 36 (2.78%)
occurrences (all)	0	1	1
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	3 / 37 (8.11%)	4 / 37 (10.81%)	6 / 36 (16.67%)
occurrences (all)	4	5	6
Rhinitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 37 (5.41%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	3	1	0

Non-serious adverse events	PF-06700841 0.3% QD	PF-06700841 3.0% QD	Pooled Vehicle BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 37 (18.92%)	8 / 37 (21.62%)	10 / 49 (20.41%)

Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 37 (2.70%)	2 / 37 (5.41%)	2 / 49 (4.08%)
occurrences (all)	1	2	2
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 37 (5.41%)	0 / 37 (0.00%)	2 / 49 (4.08%)
occurrences (all)	2	0	2
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	1 / 49 (2.04%)
occurrences (all)	1	0	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 37 (2.70%)	3 / 37 (8.11%)	3 / 49 (6.12%)
occurrences (all)	2	3	3
Rhinitis			
subjects affected / exposed	2 / 37 (5.41%)	0 / 37 (0.00%)	1 / 49 (2.04%)
occurrences (all)	2	0	1
Upper respiratory tract infection			
subjects affected / exposed	1 / 37 (2.70%)	2 / 37 (5.41%)	2 / 49 (4.08%)
occurrences (all)	1	2	2

Non-serious adverse events	PF-06700841 0.3% BID	PF-06700841 1.0% BID	PF-06700841 3.0% BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 36 (11.11%)	10 / 36 (27.78%)	2 / 38 (5.26%)
Investigations			
Blood creatine phosphokinase increased			

subjects affected / exposed	0 / 36 (0.00%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 36 (0.00%)	2 / 36 (5.56%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 36 (2.78%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 36 (5.56%)	2 / 36 (5.56%)	0 / 38 (0.00%)
occurrences (all)	2	2	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 36 (0.00%)	2 / 36 (5.56%)	1 / 38 (2.63%)
occurrences (all)	0	2	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 36 (2.78%)	7 / 36 (19.44%)	0 / 38 (0.00%)
occurrences (all)	1	7	0
Rhinitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 36 (0.00%)	0 / 38 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 36 (2.78%)	0 / 36 (0.00%)	1 / 38 (2.63%)
occurrences (all)	1	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 April 2020	Addition of an option to add an additional cohort of subjects in BID dosing arm (and corresponding vehicle arm) as stage 2 of the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported